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I 
Abstract 
Articular cartilage has a poor intrinsic repair capacity after injury and cartilage 
lesions may lead to further degeneration and osteoarthritis. Mesenchymal stem cells 
(MSCs) are a promising cell source for tissue engineering approaches to repair 
articular cartilage lesions. During in vitro chondrogenesis, MSCs express articular 
cartilage markers like collagen II and aggrecan. However, chondrogenic 
differentiating MSCs also express markers of hypertrophic chondrocytes such as 
collagen type X and alkaline phosphatise (ALP). Hypertrophy is a stage in 
endochondral bone development, e.g. in growth plate chondrocytes and ultimately 
ends in chondrocyte apoptosis and ossification. The similarity of MSC 
chondrogenesis and endochondral ossification raises concern for a tissue 
engineering application of MSCs for articular cartilage repair and suggests that 
similar mechanisms are involved in the regulation of hypertrophy in both biological 
processes. In growth plate chondrocytes, BMP signalling promotes and TGFß 
signalling inhibits hypertrophy. The goal of this thesis is to investigate the 
involvement of these pathways in the regulation of MSC hypertrophy in order to 
discover possible approaches for the modulation of this phenomenon. 
Human MSCs were differentiated chondrogenically in pellet culture in chondrogenic 
medium containing TGFß and dexamathasone. In an in vitro hypertrophy model, the 
hypertrophic phenotype was enhanced by withdrawal of TGFß and dexamethasone 
and addition of triiodothyronine (T3). Differential gene expression analysis for 
ligands, receptors and modulators of BMP and TGFß signalling and confirmation of 
the results on protein level was carried out. The activity of the respective 
intracellular signalling pathways was assessed. Furthermore, functional experiments 
using agonists and antagonists of BMP and TGFß signalling were included. 
The enhancement of the hypertrophic phenotype by the pro-hypertrophic medium 
conditions was clearly shown by increased cells size, collagen type X deposition 
and ALP activity. Differential gene expression analysis revealed up-regulation of 
BMP4, BMP receptor 1B and the BMP signalling associated transcription factor 
Runx2 upon induction of hypertrophy. Addition of BMP4 to the medium further 
enhanced hypertrophy, confirming the key role of BMP4 in the regulation of MSC 
hypertrophy in our model. In addition, it was shown that the induced hypertrophy 
could be blocked by the BMP antagonists noggin and dorsomorphin. On the other 
hand, TGFß receptor expression, the expression of the TGFß signalling associated 
II 
transcription factor Sox9 and TGFß signalling activity are reduced under pro-
hypertrophic conditions. 
In conclusion, the results show that increased BMP signalling and reduced TGFß 
signalling are both involved in the enhancement of the hypertrophic phenotype. 
These pathways are possible targets for the modulation of the amount of 
hypertrophy in MSC based cartilage tissue engineering applications. 
III 
Zusammenfassung  
Artikulärer Knorpel weist eine schlechte Regenerationsfähigkeit nach Verletzungen 
auf und Knorpelverletzungen können zu weiteren Degenerationen und Osteoarthritis 
führen. Mesenchymale Stammzellen (MSCs) sind eine vielversprechende Zellquelle 
für die Entwicklung von Tissue Engineering Produkten zur Reparatur von 
lokalisierten Knorpelschäden. In den üblicherweise verwendeten in vitro 
Chondrogenese Modellen differenzieren MSCs chondrogen und exprimieren 
typische chondrogene Marker wie Kollagen II und Aggrecan. Chondrogen 
differenzierende MSCs exprimieren jedoch auch Hypertrophiemarker wie Kollagen 
X und Alkalische Phosphatase (ALP). Hypertrophie ist ein Stadium während der 
endochondralen Knochenentwicklung, insbesondere in Wachstumsfugen-
chondrocyten und führt unweigerlich zur Apoptose der Chondrozyten und zur 
Ossifikation. Die Ähnlichkeit von MSC Chodrogenese und endochondraler 
Ossifikation macht den Einsatz von MSCs für die Entwicklung von Tissue 
Engineering Produkten zur Reparatur von Knorpelschäden bedenklich und deutet 
darauf hin dass ähnliche Mechanismen in der Regulation der Hypertrophie in beiden 
Prozessen beteiligt sind. Aus der Wachstumsfuge ist bekannt, dass verschiedene 
Wachstumsfaktorsysteme an der Regulation der hypertrophen Differenzierung 
beteiligt sind, darunter BMP und TGFß Signalling. BMP Signalling fördert die 
terminale Differenzierung und TGFß Signalling hemmt die Hypertrophie. Das Ziel 
dieser Arbeit lag darin, die Regulation der MSC Hypertrophie besser zu verstehen 
um Wege zu finden die Hypertrophie von MSCs zu hemmen. Insbesondere der 
Einfluss von BMP und TGFß Signalling auf die Hypertrophieentwicklung von MSCs 
wurde untersucht.  
Humane MSCs wurden in einem Pellet Kultur System in chondrogenem Medium 
das TGFß und Dexamethazon enthält chondrogen differenziert. In einem in vitro 
Hypertrophie Modell wurde der hypertrophe Phänotyp durch den Entzug von TGFß 
und Dexamethazon und eine Zugabe von dem Schilddrüsenhormon T3 erhöht. Eine 
differentielle Genexpressionsanalyse von Liganden, Rezeptoren und Modulatoren 
von BMP und TGFß Signalling wurde vergleichend zwischen chondrogenen und 
hypertrophen Bedingungen durchgeführt. Die Aktivität der jeweiligen Signalwege 
wurde analysiert und funktionelle Experimente mit BMP und TGFß Agonisten und 
Antagonisten wurden durchgeführt.  
IV 
Die Verstärkung der Hypertrophie unter pro-hypertrophen Bedingungen wurde 
gezeigt durch ein stark erhöhtes Zellvolumen, erhöhte Kollagen X Expression und 
gesteigerter ALP Aktivität. Die differentielle Genexpressionsanalyse zeigt, dass 
unter pro-hypertrophen Bedingungen BMP4, BMPR1B und der BMP Signalling 
assoziierte Transkriptionsfaktor Runx2 signifikant hochreguliert sind. Darüber hinaus 
führt eine Zugabe von rekombinantem BMP4 Protein zum Zellkulturmedium zu einer 
Verstärkung der Hypertrophie, was eine Schlüsselrolle von BMP4 in der Regulation 
der MSC Hypertrophie in unserem Modell untermauert. Des Weiteren konnte 
gezeigt werden, dass die induzierte Hypertrophie durch die BMP Antagonisten 
Noggin und Dorsomorphin gehemmt werden kann.  
Auf der anderen Seite ist sowohl die Expression der TGFß Rezeptoren und des 
TGFß Signalling assoziierte Transkriptionsfaktor Sox9 als auch die Aktivität des 
TGFß Signalweges unter hypertrophen Bedingungen erniedrigt.  
Zusammenfassend zeigen diese Ergebnisse dass verstärktes BMP Signalling und 
reduziertes TGFß Signalling beide zu der Erhöhung des hypertrophen Phänotyps 
beitragen. Diese Signalwege sind mögliche Ansatzpunkte für die Modulation der 
Hypertrophie in MSC basierenden Knorpelersatzprodukten. 
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1 Introduction 
Chondrogenesis is a well-coordinated developmental differentiation program by 
which cartilage is formed. Mesenchymal cells condensate and differentiate into 
chondrocytes that synthesize and secrete a characteristic matrix into the 
extracellular space. Chondrogenesis is regulated by cellular interactions, growth and 
differentiation factors that modulate cellular signalling pathways and the 
transcription of specific genes. Chondrogenesis leads to transient cartilage during 
endochondral bone formation or to permanent articular cartilage in the joints. While 
endochondral ossification is well understood, the mechanisms leading to permanent 
articular cartilage are unclear.   
1.1 Endochondral ossification 
The vertebrate limb skeleton develops through a process called endochondral 
ossification, which involves the formation of a cartilage scaffold that is ultimately 
replaced by bone.  
The cartilage template is formed by aggregation and condensation of loose 
mesenchyme. The condensing mesenchyme expresses cell adhesion and 
extracellular matrix (ECM) molecules such as N-cadherine, N-CAM, tenascin, 
versican and collagen type I. Cells located centrally differentiate to pre-chondrocytes 
that turn off the expression of mesenchymal and condensation markers and begin to 
express collagen type II and other cartilage specific markers. Cells located 
peripherally remain undifferentiated and form the perichondrium. Pre-chondrocytes 
further differentiate into fully committed chondrocytes that are characterized by an 
increased cell proliferation and the deposition of cartilage matrix. Chondrocytes 
highly express collagen type II, collagen type IX, collagen type XI and other cartilage 
markers like aggrecan. Initially small and round, chondrocytes become flattened and 
are organized into parallel, longitudinal columns. They slow down their proliferative 
activity and finally stop proliferating. Chondrocytes then differentiate towards pre-
hypertrophic chondrocytes followed by differentiation into fully differentiated 
hypertrophic chondrocytes. Hypertrophic chondrocytes are characterized by an 
increased cell size, the expression collagen type X instead of collagen type II and 
expression of high levels of the enzyme alkaline phosphatase (ALP) (Lewinson, D. 
et al., 1982; O'Keefe, R. J. et al., 1994). ALP is essential for the calcification of the 
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matrix (Anderson, H. C., 1995) and is secreted by hypertrophic chondrocytes into 
the surrounding matrix. Hypertrophic chondrocytes also express vascular 
endothelial factor (VEGF) (Gerber, H. P. et al., 1999) that promotes the invasion of 
blood vessels into the cartilage matrix. Finally, hypertrophic chondrocytes undergo 
apoptosis, blood vessel, osteoclasts and osteoprogenitor cells invade which replace 
the cartilage scaffold by bone (Figure 1 A) (Goldring, M. B. et al., 2006) (Shimizu, H. 
et al., 2007). Endochondral ossification takes place in the growth plate, which 
develops at the end of long bones and is responsible for the longitudinal growth of 
the bones. The growth plate is divided into different zones according to the 
morphology and maturation stages of the chondrocytes (Figure 1 B).  
 
 
 
Figure 1 Endochondral bone development. A Schematic representation of a developing 
endochondral bone. Endochondral skeletal development begins with the formation of a mesenchymal 
condensation. Mesenchymal cells in the centre differentiate into collagen type II expressing 
chondrocytes (blue) that differentiate to hypertrophic chondrocytes, that are characterized by 
collagen type X expression (purple). Progression to the mature growth plate includes development of 
the perichondrium (yellow) and vascular invasion. (Minina, E. et al., 2002) B Mouse tibial growth 
plate. ALP activity (blue), neutral red as counterstaining (http://www.histology-world.com 
/photoalbum/displayimage.php?album=77&pid=4579). 
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Endochondral ossification gives rise to long bones that comprise the appendicular 
skeleton and vertebrae. Apart from endochondral ossification there is a second 
developmental process that is responsible for the formation of the vertebrate 
skeleton, called intramembranous ossification. Intramembranous ossification gives 
rise to flat bones including the cranium. Both processes are initiated by 
condensation of mesenchyme, however in endochondral ossification a cartilagous 
template is formed that is subsequently transferred to bone and in intramembranous 
ossification mesenchymal cells differentiate directly into osteoprogenitor cells. 
Osteoprogenitor cells mature towards osteoblasts that deposit and mineralize the 
bone matrix.  
Endochondral ossification also takes place during secondary fracture healing. 
During fracture repair, a cartilaginous template, the callus, is built which is 
afterwards replaced by bone (Yamagiwa, H. & Endo, N., 2009).  
1.1.1 Regulation of endochondral ossification  
The different steps of endochondral bone development are regulated by a number 
of signalling molecules including bone morphogenetic proteins (BMPs), transforming 
growth factor ß (TGFß), fibroblast growth factors (FGFs), parathyroid hormone-
related peptide (PTHrP), Indian hedgehog (Ihh) and Wnts. 
1.1.1.1 TGFß superfamily 
The TGFß superfamily consists of signalling molecules including TGFß, BMPs, 
activins, inhibins and growth and differentiation factors (GDFs). These growth 
factors have been implicated in the regulation of various processes during 
embryonic development including cell growth and differentiation, pattern formation 
and tissue specification (Kingsley, D. M., 1994; Hogan, B. L., 1996). 
BMP signalling pathway  
BMPs form a subgroup within the TGFß superfamily. BMPs are dimeric proteins and 
more than 20 BMP related proteins have been characterized. In the main signalling 
pathway, BMPs bind to a heterodimeric receptor complex composed of type I and 
type II serine/threonine kinase receptors (Derynck, R. & Feng, X. H., 1997). Upon 
ligand binding, the type II receptor phosphorylates the type I receptor. One type II 
and three different type I receptors transduce BMP signals: BMP receptor 1A 
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(BMPR1A, ALK3), BMP receptor 1B (BMPR1B, ALK6) and ALK2. Activated type I 
receptor phosphorylates and thereby activates intracellular signalling molecules, the 
Smads. In the case of BMP signalling Smad1, 5, 8 are activated. Activated Smad1, 
5, 8 build a complex with the co-Smad4 and this complex moves into the nucleus 
and regulates gene expression (Figure 2 A).  
The BMP signalling pathway can be regulated at different levels. First, there are two 
inhibitory Smads, Smad6 and Smad7, that inhibit or turn off BMP type I receptor 
mediated phosphorylation of Smad1, 5, 8. Secondly, a considerable degree of 
regulation occurs on the level of ligand availability. Extracellular BMP-specific 
antagonists like noggin, chordin, follistatin and gremlin complex with BMPs and 
prevent their binding to the receptor (Zimmerman, L. B. et al., 1996; Hsu, D. R. et 
al., 1998; Iemura, S. et al., 1998; Khokha, M. K. et al., 2003). Furthermore co-
receptors modulate BMP signalling. The pseudoreceptor BAMBI (BMP and activin 
membrane-bound inhibitor) is a transmembrane protein with structural similarity to 
type I receptors of the TGFß superfamily, but has a shorter intracellular domain 
which exhibits no enzymatic activity (Onichtchouk, D. et al., 1999; Grotewold, L. et 
al., 2001). BAMBI inhibits TGFß and BMP signalling by blocking the interaction 
between type I and type II receptors (Onichtchouk, D. et al., 1999). BAMBI is tightly 
co-expressed with BMP4 during embryonic development and may act as a negative 
feedback regulator of BMP signalling (Onichtchouk, D. et al., 1999; Grotewold, L. et 
al., 2001). Finally a considerable degree of crosstalk exists between the BMP 
signalling pathway and other signalling pathways.  
Another strategy to artificially inhibit BMP signalling is the use of small molecule 
inhibitors. Dorsomorphin has been shown to block BMP-induced Smad1, 5, 8 
phosphorylation while having no effect on TGFß-induced Smad2, 3 activation (Yu, 
P. B. et al., 2008). The heterocyclic core structure of dorsomorphin binds to the ATP 
binding site in the kinase domain of the type I receptors and inhibits their kinase 
domain (Yu, P. B. et al., 2008; Wrighton, K. H. et al., 2009) (Figure 2 B).  
In addition to the Smad-dependent pathway, BMPs can also activate Smad-
independent pathways including the mitogen-activated-protein kinases (MAPK) 
pathway. BMPs can signal by activating TGFß-activated kinase 1 (TAK1) which 
interacts with MEKK1 and activates p38 or by activating Ras/Erk1/2 (Derynck, R. & 
Feng, X. H., 1997). 
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TGFß signalling pathway  
Similar to BMP signalling, TGFß signalling is initiated by binding of ligands to a 
heterodimeric serine/threonine kinase receptor complex that is composed of TGFß 
type I and type II receptors. The TGFß type II receptor (TGFßR2) then 
phosphorylates the TGFß type I receptor (TGFßR1, ALK-5) which in turn 
phosphorylates and thereby activates Smad proteins. In contrast to BMP signalling, 
TGFß signalling activates Smad2, 3. Phosphorylated Smad2, 3 forms a complex 
with Smad4 and accumulates in the nucleus to regulate gene transcription (Figure 2 
A). Similar to BMP signalling, TGFß signalling can be modulated at different levels. 
Inhibitory Smad6 and Smad7 interfere with the activation of Smad2 and Smad3. 
Betaglycan and endoglin are TGFß co-receptors that modulate TGFß signalling. 
Betaglycan is a membrane-anchored proteoglycan that binds TGFß1, TGFß2 and 
TGFß3 with high affinity (Massague, J., 1998). Betaglycan lacks an intracellular 
signalling domain but can facilitate TGFß binding to the signalling receptors. 
Endoglin is a membrane bound glycoprotein that is able to bind TGFß1 and TGFß3 
(Massague, J., 1998). Whereas betaglycan seems to increase TGFß signalling, 
endoglin is assumed to inhibit TGFß signalling (Letamendia, A. et al., 1998; Perez-
Gomez, E. et al., 2007). In addition, TGFß signalling activity is controlled by the 
conversion of latent TGFß to active TGFß. TGFß is normally secreted in an inactive, 
latent form. TGFß1, TGFß2 and TGFß3 are synthesized with large amino-terminal 
prodomains which are required for the correct folding and dimerization of the 
carboxy-terminal growth factor domain (Gray, A. M. & Mason, A. J., 1990). The 
propeptides which are known as the latency-associated proteins (LAPs) are cleaved 
from the mature TGFß dimer after secretion but non-covalent association persists 
between the growth factor domain and prodomain. Another protein called latent 
TGF-ß binding protein (LTBP) binds to this complex. Activation of TGFß requires the 
release of TGFß from the LAP and LTBP. The process of TGFß activation is not 
fully understood, however, the mechanism of TGFß activation in the growth plate 
defined thus far includes matrix metalloproteinases or other proteases and acidic 
conditions (Pedrozo, H. A. et al., 1999; D'Angelo, M. et al., 2001).  
TGFß signalling can be inhibited artificially with the TGFßR1 inhibitor SB431542. 
SB431542 is a potent inhibitor of TGFßR1 kinase activity and has been shown to 
inhibit the in vitro phosphorylation of Smad3 (Callahan, J. F. et al., 2002) while 
having no influence on BMP signalling (Inman, G. J. et al., 2002) (Figure 2 B).  
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Figure 2 BMP and TGFß signalling pathways. A BMPs bind to their receptors and activate 
intracellular Smad1, 5, 8 proteins that move into the nucleus and activate target gene expression. 
One important downstream target of BMP signalling is Runx2. TGFßs bind to their receptors and 
activate intracellular Smad2, 3 proteins that move into the nucleus and activate target gene 
expression. One important downstream target of TGFß signalling is Sox9. B Modulators of 
BMP/TGFß signalling. Soluble BMP antagonists (Noggin, Chordin, Gremlin, Follistatin) prevent the 
interaction of BMPs with their receptors. Inhibitory Smad6, 7 inhibit the phosporylation of Smad1, 5, 8 
and Smad2, 3 respectively. Dorsomorphin inhibits BMPR1 induced phosphorylation of Smad1, 5, 8 
and SB431542 inhibits TGFßR1 induced phosphorylation of Smad2, 3. Bambi inhibits the formation 
of type I and II receptor complexes.  
 
The role of BMP signalling in the regulation of endochondral ossification 
During endochondral ossification, genes for BMPs and their receptors are 
expressed in distinct spatial and temporal patterns. BMP2, BMP4 and BMP7 are 
expressed in the perichondrium and are believed to regulate cartilage formation and 
development (Macias, D. et al., 1997; Zou, H. et al., 1997). Different studies clearly 
demonstrated that BMPs have multiple roles during the different stages of 
endochondral bone development. First, BMP signalling promotes the formation of 
mesenchymal condensations. Noggin expression in early chick limbs suppresses 
the formation of mesenchymal condensations (Pizette, S. & Niswander, L., 2000). 
Secondly, BMPs stimulate chondrogenic differentiation (Chen, P. et al., 1991; 
Cancedda, R. et al., 1995; Duprez, D. M. et al., 1996; Pizette, S. & Niswander, L., 
2000; Carlberg, A. L. et al., 2001; Tsumaki, N. et al., 2002). Finally, BMP signalling 
plays a crucial role during chondrocyte maturation. BMPs promote the terminal 
differentiation of growth plate chondrocytes to hypertrophic chondrocytes. In vitro 
studies showed that cultured embryonic chondrocytes are induced to undergo 
hypertrophy and increase the expression of hypertrophic markers including collagen 
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type X and ALP in the presence of BMPs (Suzuki, F., 1992; Rosen, V. et al., 1994; 
Leboy, P. S. et al., 1997; Volk, S. W. et al., 1998; Grimsrud, C. D. et al., 1999). In 
contrast, inhibition of BMP signalling prevents chondrocyte hypertrophy (Volk, S. W. 
et al., 2000; Grimsrud, C. D. et al., 2001). In vivo studies showed that 
overexpression of BMP4 in the cartilage of transgenic mice results in increased 
hypertrophic zone indicating increased differentiation into hypertrophic chondrocytes 
whereas overexpression of the BMP inhibitor noggin leads to a lack of hypertrophic 
chondrocytes (Tsumaki, N. et al., 2002). Furthermore overexpression of noggin or 
chordin in the developing chick limb bud prevents chondrocyte hypertrophy and the 
expression of hypertrophic markers like collagen type X and ALP (Pathi, S. et al., 
1999; Zhang, D. et al., 2002).  
Other factors that induce chondrocyte hypertrophy also appear to act through BMP 
signalling. Thyroid hormone is one of the major systemic hormones influencing 
growth during childhood. Untreated hypothyroidism results in growth retardation and 
delayed skeletal maturation (Williams, G. R. et al., 1998; Harvey, C. B. et al., 2002) 
and hypothyroid rats display a disorganized growth plate with decreased 
hypertrophic zone (Stevens, D. A. et al., 2000). The thyroid gland releases thyroxine 
(T4), which is transferred to tri-iodothyronine (T3), enters the nucleus and binds to 
thyroid hormone receptors (TRs) that function as ligand activated transcription 
factors. The receptors bind to specific DNA sequences (T3 responsive elements, 
TREs) and modulate transcriptional activity of thyroid hormone-responsive genes 
(Zhang, 2000). Thyroid hormone induces collagen type X expression and other 
hypertrophy associated marker in cultured mouse and chick growth plate 
chondrocytes (Bohme, K. et al.; Ballock, R. T. & Reddi, A. H.; Alini, M. et al., 1996; 
Rabier, B. et al.). The effect of thyroid hormone seems to be mediated by BMP 
signalling. In mouse chondrocytes T4 induces hypertrophy through induction of 
BMP2 and this effect can be blocked by addition of the BMP antagonist noggin 
(Ballock, R. T. & O'Keefe, R. J., 2003). In chick chondrocytes thyroid hormone 
increases hypertrophy through BMP4 (Lassova, L. et al., 2009). Similarly, the 
induction of hypertrophy by retinoic acid seems to be mediated by BMP signalling.  
The role of TGFß signalling in the regulation of endochondral ossification 
TGFß is expressed in condensing mesenchyme and during early stages of 
chondrocyte differentiation but not in hypertrophic chondrocytes (Pelton, R. W. et 
al., 1990; Millan, F. A. et al., 1991). TGFß signalling has been shown to stimulate 
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chondrogenesis in vitro and in vivo. In vitro studies showed that TGFß promotes 
chondrogenic differentiation in mesenchymal cells and chondroblasts (Seyedin, S. 
M. et al., 1986; Schofield, J. N. & Wolpert, L., 1990; Leonard, C. M. et al., 1991; 
Lorda-Diez, C. I. et al.). In vivo, it was shown that injection of TGFß1 into the 
periosteum induces chondrocyte differentiation and cartilage formation (Joyce, M. E. 
et al.; Chimal-Monroy, J. & Diaz de Leon, L., 1997). In addition to regulating 
chondrogenic differentiation, TGFß plays a significant role in the regulation of 
chondrocyte maturation. In contrast to BMP signalling, TGFß signalling inhibits 
chondrocyte terminal differentiation and hypertrophy in vitro and in vivo. In vitro 
studies showed that TGFß inhibits hypertrophy and the expression of hypertrophy 
associated genes like collagen type X and ALP in cultured embryonic chondrocytes 
(Ballock, R. T. et al., 1993; Bohme, K. et al., 1995; Ferguson, C. M. et al., 2000). In 
an in vivo model of chick embryonic limb development, Ferguson et al showed that 
increased level of TGFß applied to the developing skeletal element inhibits 
chondrocyte hypertrophy (Ferguson, C. M. et al., 2004) and loss of function models 
of TGFß signalling result in premature chondrocyte maturation in mice (Serra, R. et 
al., 1997; Yang, X. et al., 2001). 
In summary, both BMP and TGFß signalling promote chondrogenic differentiation, 
but have opposing effects on later differentiation steps during skeletal development. 
BMP signalling promotes terminal differentiation of embryonic chondrocytes and 
TGFß signalling inhibits chondrocyte hypertrophy (Figure 3). Apart from BMP and 
TGFß signalling other signalling pathways are also involved in the regulation of 
endochondral ossification. 
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Figure 3 Regulation of endochondral ossification. BMP and TGFß signalling promote 
chondrogenic differentiation. BMP signalling promotes and TGFß signalling inhibits hypertrophic 
differentiation.  
 
1.1.1.2 Ihh/PTHrP signalling 
Ihh is part of the Ihh/PTHrP feedback loop that regulates the rate at which growth 
plate chondrocytes leave the proliferative zone and enter the differentiation process 
towards hypertrophic chondrocytes (Vortkamp, A. et al.). Ihh is expressed by pre-
hypertrophic chondrocytes and the hedgehog receptor patched (PTCH1) is 
expressed in surrounding perichondrial cells. Chondrocytes that are beginning to 
undergo hypertrophic differentiation express Ihh which relays a signal back to the 
perichondrium to induce the expression of PTHrP (Vortkamp, A. et al.). The PTHrP 
receptor is primarily found in the transitional region where the switch from 
proliferating to hypertrophic chondrocytes takes place (Amizuka, N. et al., 1994). 
Released PTHrP from the perichondrium binds to its receptors in the pre-
hypertrophic zone and delays hypertrophic differentiation by maintaining cells in a 
proliferating state. In vivo studies showed that inhibition of PTHrP signalling in mice 
leads to an advanced onset of hypertrophic differentiation (Amizuka, N. et al., 1994) 
and activation of PTHrP signalling leads to delayed hypertrophic differentiation 
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(Schipani, E. et al., 1997). Similar to this, in mice lacking Ihh, premature 
hypertrophic differentiation occurs (St-Jacques, B. et al., 1999). 
The Ihh/PTHrP system seems to play a major role in the regulation of chondrocyte 
maturation during prenatal development, whereas it is believed that postnatally 
TGFß signalling seem to control chondrogenic maturation in adult animals. The 
distance between the growth plate and the articular surface is too large for paracrine 
Ihh/PTHrP feedback loop and recent studies have indicated that Ihh is not produced 
by the growth plate of postnatal animals (Iwasaki, M. et al., 1997). Several lines of 
evidence indicate that TGFß resume the role of PTHrP as the key inhibitor of 
chondrocyte differentiation in adolescence. A work from Pedrozo et al demonstrated 
that mice deficient for the TGFß signalling associated transcription factor Smad3 
have a completely normal skeleton at birth but within few weeks after birth they 
begin to exhibit cartilage abnormalities including premature hypertrophy (Pedrozo, 
H. A. et al., 1998). 
1.1.1.3 FGF signalling 
Many FGFs and four of the FGF receptors are expressed during endochondral bone 
formation (Ornitz, D. M., 2005) indicating that FGF signalling is crucially involved in 
chondrocyte differentiation and maturation. FGF receptor 1 (FGFR1) is expressed in 
loose mesenchyme, while FGFR2 is expressed in condensing mesenchyme. 
FGFR3 is expressed by proliferating and pre-hypertrophic chondrocytes and FGFR1 
is again up-regulated in pre-hypertrophic and hypertrophic chondrocytes. The 
function of FGFR3 is best understood. The importance of FGFR3 in skeletal 
development was revealed with the discovery that achondroplasia, the most 
common genetic form of dwarfism in humans is caused by a point mutation in the 
transmembrane domain of the FGFR3 (Rousseau, F. et al., 1994; Shiang, R. et al., 
1994). The point mutation leads to an activation of the FGFR3 in the absence of the 
ligand. Achondroplasia is characterized by reduced growth of long bones and the 
growth plate of these patients shows a reduced zone of proliferating chondrocytes 
(Briner, J. et al., 1991). Similar to this, in vivo studies showed that activation of 
FGFR3 leads to an inhibition of proliferation (Ornitz, D. M., 2005) and knockdown of 
FGFR3 leads to a prolonged bone growth accompanied by expansion of 
proliferating chondrocytes within the growth plate (Colvin, J. S. et al., 1996; Deng, 
C. et al., 1996). Thus, FGF signalling through FGFR3 inhibits proliferation. Different 
FGFs are capable of activating FGFR3, the most important FGF during 
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endochondral skeleton development seems to be FGF18 (Ornitz, D. M., 2005). 
Knockdown of FGF18 leads to an increase in chondrocyte proliferation that closely 
resembles the knockdown of FGFR3 (Ohbayashi, N. et al., 2002). In addition, in 
FGF18 knockdown mice delayed ossification is observed indicating a role of FGF 
signalling in the regulation of chondrocyte maturation. This delay may reflect the 
lack of activation of FGFR1 in hypertrophic chondrocytes. In addition in vitro studies 
demonstrated that FGF signalling accelerates terminal differentiation of hypertrophic 
chondrocytes (Minina, E. et al., 2002).  
1.1.1.4 Wnt signalling 
Canonical Wnt signalling has also been implicated in the regulation hypertrophy 
during endochondral ossification. The canonical Wnt/ß-catenin pathway is initiated 
by binding of Wnts to the Frizzled receptor and its co-receptor (low-density 
lipoprotein receptor-related protein 5 and 6 (LRP5/6)). In the absence of canonical 
Wnt signalling cytosolic ß-catenin is phosphorylated by the glycogen synthase 
kinase (GSK-3ß) and degraded by the ubiquitin/proteasome pathway. Upon 
activation of the canonical Wnt signalling pathway, the GSK-3ß is inhibited resulting 
in decreased ß-catenin phosphorylation and degradation. ß-catenin accumulates in 
the cytoplasm and moves into the nucleus to form a complex with the transcription 
factor Lef-1/TCF and activates transcription of Wnt target genes. The canonical Wnt 
signalling pathway is regulated by different extracellular and intracellular proteins. 
Extracellular inhibitors include secreted frizzled-related proteins (sFRP) that bind to 
Wnts and prevent the interaction with the receptor and dickkopfs (DKKs) that block 
Wnt signalling through the co-receptor LRP5/6 (Kawano, Y. & Kypta, R., 2003). 
Members of the canonical Wnt signalling family are highly expressed in 
mesenchymal cells committed to the chondrogenic lineage, are down regulated 
during early chondrogenic differentiation and up-regulated during hypertrophy where 
it promotes chondrocyte hypertrophy (Day, T. F. et al., 2005; Hill, T. P. et al., 2005; 
Tamamura, Y. et al., 2005). Mice deficient for the Wnt inhibitor sFRP-1 exhibit 
accelerated hypertrophic chondrocyte maturation in vivo and in vitro (Gaur, T. et al., 
2006).  
Wnts also signal through a ß-catenin independent mechanism, the non-canonical 
Wnt pathway. The non-canonical Wnt pathway involves the activation of the protein 
kinase C (PKC) leading to increased intracellular calcium concentration. A recent 
study demonstrated that inhibition of non-canonical Wnt signalling (via inhibition of 
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PKC) delays chondrocyte maturation shown by a decreased hypertrophic zone (Tu, 
X. et al., 2007).  
1.1.1.5 Transcriptional regulation during endochondral ossification 
Major progress has been made over the last years in understanding the 
transcriptional regulation of chondrocyte differentiation during embryonic limb 
development. Sox9 and Runx2 seem to play a key role in the regulation of 
chondrogenesis. Sox9 plays a critical role in chondrogenic differentiation and 
inhibits terminal differentiation while Runx2 has been shown to promote chondrocyte 
hypertrophy (Figure 4).  
Sox9 
Sox9 belongs to the SRY (sex-determining region on the Y chromosome) family and 
contains the HMG (high mobility group) box DNA binding domain. During 
chondrogenesis, Sox9 is expressed in mesenchymal cells and in proliferating 
chondrocytes but not in hypertrophic chondrocytes (Ng, L. J. et al., 1997; Zhao, Q. 
et al., 1997). Sox9 is essential for the initiation of chondrogenesis. In chimeric mice, 
cells with no functional Sox9 fail to differentiate into chondrocytes and could not 
express chondrogenic specific markers like collagen type II and aggrecan (Bi, W. et 
al.). In addition, Sox9 is required for the maintenance of chondrogenic 
differentiation. Inactivation of Sox9 in the mouse embryo in collagen type II 
expressing cells results in the formation of pre-cartilagous condensations but pre-
chondrocytes were not able to undergo further chondrogenic differentiation 
(Akiyama, H. et al., 2002). Sox9 expression is down-regulated in hypertrophic 
chondrocytes indicating that Sox9 delays chondrocyte hypertrophy. Heterozygotous 
Sox9 mouse foetuses featured prematurely mineralized cartilages and extended 
hypertrophic zones in the growth plate (Bi, W. et al., 1999). Furthermore, in mice 
that expressed Sox9 under the control of the collagen type II promoter cartilage 
mineralization was delayed (Akiyama, H. et al., 2002). Two additional Sox family 
members, Sox5 and Sox6, are not expressed in early mesenchymal condensations 
but are co-expressed with Sox9 during chondrocyte differentiation (Lefebvre, V. et 
al., 1998). Sox5 and Sox6 are required for sufficient expression of collagen type II 
and aggrecan during chondrocyte differentiation (Smits, P. et al., 2001). Sox9 and 
Sox5/Sox6 cooperate to activate collagen type II and other cartilage specific genes 
(Lefebvre, V. et al., 1998).  
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Sox9 expression seems to be regulated by TGFß (Chimal-Monroy, J. et al., 2003). 
TGFß has been shown to promote chondrogenesis especially through Smad3 
mediated TGFß signalling (Furumatsu, T. et al.). Smad3 stimulates transcriptional 
activity of Sox9 and Smad3 forms a complex with Smad2, Smad4 and Sox9 and 
activates expression of Collagen type II (Furumatsu, T. et al., 2005; Furumatsu, T. 
et al., 2009). In addition, Sox9 expression seems to be regulated by BMP signalling. 
Inactivation of both BMPR1A and BMPR1B in mice results in a lack of Sox9 
expression (Yoon, B. S. et al., 2005). 
Sox9 has been shown to activate the expression of cartilage specific genes like 
collagen type II, aggrecan and collagen type XI (Lefebvre, V. et al., 1997; 
Bridgewater, L. C. et al., 1998; Sekiya, I. et al., 2000). 
Runx2 
Runx2 is a transcription factor that belongs to the runt-domain gene family (Komori, 
T. & Kishimoto, T., 1998). It has a DNA-binding domain runt, which is homologous 
with the Drosophila pairrule gene runt (Kania, M. A. et al., 1990). Three runt domain 
genes have been identified (Runx1, Runx2, Runx3). Runx2 is weakly expressed in 
resting and proliferating chondrocytes and its expression increases according to 
chondrocyte maturation with the highest expression in terminal differentiated 
hypertrophic chondrocytes (Inada, M. et al., 1999; Kim, I. S. et al., 1999; Takeda, S. 
et al., 2001). Runx2 plays an important role in chondrocyte hypertrophy during the 
process of endochondral ossification. It has been shown that, in vitro, Runx2 
stimulates chondrocyte maturation and the expression of hypertrophy markers like 
collagen type X and ALP (Enomoto, H. et al., 2000; Ueta, C. et al., 2001). In vivo, in 
Runx2 deficient mice chondrocyte differentiation is blocked before pre-hypertrophic 
state. The skeleton of these mice consists mainly of cartilage that is composed of 
collagen type II expressing chondrocytes with decreased numbers of hypertrophic 
collagen type X expressing chondrocytes (Komori, T. et al., 1997; Inada, M. et al., 
1999). Ueta et al generated transgenic mice that overexpressed Runx2 or 
expressed a dominant negative form of Runx2 in chondrocytes under the control of 
the collagen type II promoter. Overexpression of Runx2 leads to accelerated 
chondrocyte maturation. Most skeletal elements showed massive mineralization. 
Interestingly, even chondrocytes that normally never undergo hypertrophy like 
chondrocytes that residue in articular cartilage became hypertrophic. These mice 
failed to form most of their joints because articular cartilage underwent the 
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endochondral pathway and cavitation did not take place. Transgenic expression of a 
dominant negative form of Runx2 blocks hypertrophic differentiation. Most skeletal 
elements were uncalcified cartilaginous tissues composed of immature 
chondrocytes expressing collagen type II but not collagen type X (Ueta, C. et al., 
2001). Furthermore expression of Runx2 in non-hypertrophic chondrocytes induced 
chondrocyte hypertrophy and endochondral ossification (Takeda, S. et al., 2001). In 
addition to Runx2, Runx3 seems to promote chondrocyte hypertrophy (Yoshida, C. 
A. et al., 2004).  
Runx2 expression seems to be regulated by BMP signalling. BMP2, 4 and 7 have 
been shown to induce Runx2 expression (Tsuji, K. et al., 1998; Lee, K. S. et al.). 
Other signalling molecules that have been implicated in the regulation of Runx2 
expression are retinoids (Jimenez, M. J. et al., 1999), FGF (Zhou, Y. X. et al., 2000) 
and Wnts (Gaur, T. et al., 2005). Furthermore, TGFß/Smad 3 and PTHrP suppress 
Runx2 expression (Alliston, T. et al., 2001; Kang, J. S. et al., 2005; Guo, J. et al., 
2006).  
Several genes, that are specific for hypertrophic chondrocytes, have been 
characterized as Runx2 targets. Among them osteocalcin (Geoffroy, V. et al., 2002), 
collagen type X (Leboy, P. et al., 2001), matrix metalloproteinase (MMP)-13 
(Jimenez, M. J. et al., 1999) and VEGF (Zelzer, E. et al., 2001). Interestingly, BMP 
signalling associated transcription factors Smad1, 5, 8 have been shown to interact 
with Runx2 at the collagen type X promoter to induce its gene expression (Leboy, P. 
et al., 2001).  
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Figure 4 Transcriptional regulation of endochondral ossification. Sox9 together with Sox 5/6 
promote chondrogenic differentiation and Sox9 inhibits the terminal differentiation of chondrocytes. 
Runx2/3 promote hypertrophic differentiation of chondrocytes.  
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1.2 Articular cartilage  
Apart from the formation of transient cartilage during endochondral ossification, 
permanent articular cartilage develops in the joints, that is spared from hypertrophy. 
The origin of these articular chondrocytes is largely unknown. Recent evidence 
suggests that articular chondrocytes arise from a subpopulation of early 
chondrocytes (Hyde, G. et al., 2007; Koyama, E. et al., 2008). These cells escape 
the developmental program that involves the differentiation into hypertrophic 
chondrocytes that occurs during endochondral ossification, differentiate into articular 
chondroblasts and at the end of postnatal development become articular 
chondrocytes which maintain articular surfaces throughout life. The mechanism how 
articular chondroblasts escape growth plate maturation are relatively unknown. 
Permanent articular chondrocytes can be distinguished from transient growth plate 
chondrocytes by the expression of matrilin-1 and Gdf5 (Hyde, G. et al., 2007; 
Koyama, E. et al., 2008). Pacifici et al postulated that articular chondrocytes derive 
from Gdf5 expressing joint progenitors and growth plate chondrocytes derive from 
Gdf5 negative cells likely representing the bulk of the original condensing limb 
mesenchyme (Koyama, E. et al., 2008). 
After skeletal growth is completed, articular chondrocytes rarely divide and normally 
never undergo hypertrophy. They express cartilage specific markers like collagen 
type II, aggrecan and Sox9 (Davies, S. R. et al., 2002). Runx2 is not expressed in 
articular chondrocytes (Kuboki, T. et al., 2003). However in osteoarthritis (OA), a 
joint degenerative disease, articular chondrocytes can undergo hypertrophy and 
terminal differentiation and express hypertrophic markers like collagen type X and 
osteopontin (Girkontaite, I. et al., 1996; Pullig, O. et al., 2000), indicating that their 
differentiation state, although normally permanent, may be transient under 
pathologic conditions.  
1.2.1 Composition of articular cartilage 
The function of articular chondrocytes is to built, maintain and remodel the abundant 
ECM of the articular cartilage. Articular cartilage is a specialised tissue that coves 
the surfaces of bones in diarthrodial joints, where one bone articulates with another 
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and provides joints with a low-friction, gliding and wear-resistant surface that 
provides shock absorbance and high load bearing capability. 
The articular chondrocyte is the only cell type that is present in articular cartilage. 
The cell density is relatively low and chondrocytes occupy less than 10% of the total 
volume. Each chondrocyte is surrounded by its ECM and has few cell-cell contacts. 
The ECM of articular cartilage consists of a collagen fibre network that is comprised 
primarily of collagen type II (80 % to 90 % of the collagen content) and secondary 
collagen type IX and collagen type XI (Poole, A. R. et al., 2001). The collagen 
network entraps a highly hydrated gel of proteoglycans and glycoproteins. 
Proteoglycans consist of a core protein that is covalently linked to unbranched 
polysaccharide chains called glycosaminoglycans (GAGs). Aggrecan is the most 
abundant proteoglycan and is almost unique to cartilage. Aggrecan binds over 100 
GAG chains and forms enormous aggregates by binding to linear chains of 
hyaluronan with the help of the link protein Crtl1. Other proteins that are present in 
the cartilage ECM are fibronectin, cartilage oligomeric matrix protein and the smaller 
proteoglycans biglycan, decorin and fibromodulin (Figure 5). 
The ECM of articular cartilage is divided into different regions dependent on the 
proximity to the chondrocytes. These zones are the pericellular, territorial and 
interterritorial. The pericellular region surrounds the chondrocyte and contains 
proteoglycans and non-collagenous matrix components and little or no collagen 
fibrils. The territorial zone surrounds the pericellular region and is composed of 
collagen fibrils that form a fibrillar network and serves to protect chondrocytes from 
mechanical impact (Guilak, F. & Mow, V. C., 2000). The interterritorial zone is the 
largest region and contributes most to the mechanical properties of articular 
cartilage (Mow, V. C. & Guo, X. E., 2002). It consists of large collagen fibrils and the 
majority of proteoglycans. 
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Figure 5 Articular cartilage. A Articular cartilage covers the bones in the joints (Setton, L., 2008). B 
Extracellular matrix of articular cartilage. Three classes of proteins exist in articular cartilage: 
collagens (mostly collagen type II); proteoglycans (primarily aggrecan); and other non-collagenous 
proteins (including link protein, fibronectin, cartilage oligomeric matrix protein) and the smaller 
proteoglycans (biglycan, decorin and fibromodulin) (Chen, F. H. et al., 2006). 
 
 
Furthermore articular cartilage can be divided into four distinct zones: superficial 
tangential, middle, deep and calcified. Within each zone the composition and 
organization of the ECM and the shape and arrangement of the chondrocytes varies 
(Figure 6). 
 
Introduction 
19 
 
 
Figure 6 Schematic (A) and scanning electron micrographs (B) of the organization of articular 
cartilage. In the superficial tangential zone (STZ), collagen fibrils lie nearly parallel to the surface. In 
the middle zone, they assume a more random alignment. In the deep zone, they lie nearly 
perpendicular to the articular surface (Flik, 2007).  
 
 
1.2.2 Repair capacity of articular cartilage 
The repair capacity of articular cartilage is very limited (Buckwalter, J. A. & Mankin, 
H. J., 1998). Articular cartilage defects caused by trauma or disease such as 
osteoarthritis are not repaired properly. The low cell density within cartilage and the 
low proliferative activity reduces the likelihood of local chondrocytes to contribute to 
self-regeneration. A defect that is constricted to the cartilage layer fails to heal 
spontaneously (Kim, H. K. et al., 1991). Resident articular chondrocytes do not 
migrate to the lesion and no production of reparative matrix occurs. However, if the 
defect penetrates the underlying layer of subchondral bone, a limited spontaneous 
repair occurs. Damage to the subchondral bone results in migration of 
mesenchymal stem and progenitor cells to the injured site and promotes cartilage 
repair. However, this process normally leads to the formation of less durable 
fibrocartilage rather than hyaline cartilage (Steadman, J. R. et al., 2001).  
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1.2.3 Current treatment strategies for the repair of articular 
cartilage lesions 
There are different treatment strategies for the repair of articular cartilage defects 
that are currently in clinical use (Figure 7).  
 
Bone marrow stimulation 
The principle of this technique is to stimulate a spontaneous repair reaction by 
mechanical penetration of the subchondral bone. Penetration of the subchondral 
bone plate disrupts the subchondral blood vessels. This leads to the formation of a 
fibrin clot that fills the bone defect and covers the surface of the chondral defect. 
Mesenchymal stem cells migrate into the clot, proliferate and form fibrocartilage. 
Different modifications among this technique include subchondral drilling and 
microfracture. The microfracture technique was elaborated by Steadman 
(Steadman, J. R. et al., 1999) and is now a days the most common technique. Very 
small micro-wholes are generated across the articular cartilage lesion at a distance 
3-4 mm apart and down to a depth of 4 mm. This technique leads to the formation of 
a fibrocartilage repair tissue, that is inferior to normal hyaline cartilage in terms of 
mechanical properties (Buckwalter, J. A. & Mankin, H. J., 1998; Hunziker, E. B., 
2002). However, especially in young patients good clinical results with improved 
joint functionality and relief from pain have been reported (Blevins, F. T. et al., 1998; 
Sledge, S. L., 2001). This technique is limited to small sized focal cartilage lesions.  
 
Mosaicplasty (Osteochondral grafts)  
This technique was first described in 1993 and since then widely used for the 
treatment of chondral and osteochondral defects (Matsusue, Y. et al., 1993). 
Cylindrical osteochondral grafts are removed from a non-affected, low-weight-
bearing area and transplanted into cylindrical wholes that are prepared at the site of 
the cartilage defect. Good clinical results were described by different studies 
(Matsusue, Y. et al., 1993; Jakob, R. P. et al., 2002; Hangody, L. & Fules, P., 2003; 
Chow, J. C. et al., 2004). However, removing osteochondral grafts from normal sites 
of a joint leads to the destruction of healthy tissue and is a major limitation for this 
technique. Mosaicplasty is used in small to medium sized focal defects.  
 
Introduction 
21 
Autologous chondrocyte transplantation (ACT) 
The autologous chondrocyte transplantation (ACT) technique was introduced in 
1987. Since then this technique has been widely performed, especially for the 
treatment of large chondral defects (>4 cm2). ACT is based on the implantation of a 
suspension of cultured autologous chondrocytes beneath a tightly sealed periosteal 
flap. In the first step of the procedure a small biopsy of articular cartilage is 
harvested from a healthy, non-affected and minor-weight-bearing area of cartilage. 
The chondrocytes are released from the tissue with enzymatic digestion of the ECM 
and cultured in vitro to increase the number of cells in order to provide a sufficient 
number to fill a focal defect of articular cartilage. After the culture period of about 2 
to 3 weeks the chondrocytes are implanted into the cartilage lesion and coved by a 
periosteal tissue flap. After implantation, the chondrocytes begin to produce a 
cartilagous matrix that gradually fills out the cartilage defect (Dell'Accio, F. et al., 
2003). ACT has demonstrated significant and durable benefits for the patients in 
terms of improved function and diminished pain with the formation of a hyaline or 
hyaline-like repair tissue (Brittberg, M. et al., 1994; Peterson, L. et al., 2000; 
Peterson, L. et al., 2002; Peterson, L. et al., 2003). However, adverse events like 
periosteal hypertrophy and periosteal graft delamination have been reported after 
classical ACT (Peterson, L. et al., 2000; Marlovits, S. et al., 2006; Wood, J. J. et al., 
2006).  
Therefore modern modifications of this technique were developed to overcome 
these problems. In the matrix-associated autologous chondrocyte transplantation 
(MACT) chondrocytes are imbedded in a three-dimensional matrix and then 
transplanted into cartilage defects (Minas, T. & Peterson, L., 1999; Marlovits, S. et 
al., 2006). The matrices with seeded cells are trimmed to exactly match the defect 
size and are implanted into the defect without the use of periosteal covers. Different 
biomaterials for the MACT have been tested. Among them collagen scaffolds, 
hyaluronan-based biodegradable polymer scaffolds (Pavesio, A. et al., 2003; 
Marcacci, M. et al., 2005) and polymers of poly-actin and poly-glactin (Erggelet, C. 
et al., 2003).  
However, there are several limitations for the use of this technique. The limited 
proliferative capacity of differentiated chondrocytes poses a major problem in 
providing adequate cell numbers for the transplantation therapy (Dozin, B. et al., 
2002), ex vivo monolayer expansion before transplantation leads to rapid cell 
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dedifferentiation and conversion into fibroblasts-like cells (Schnabel, M. et al., 2002; 
Thirion, S. & Berenbaum, F., 2004). In addition removal of articular chondrocytes 
covers a risk of morbidity at the donor site.  
 
 
 
Figure 7 Cartilage repair techniques. A Microfracture (Schewe, 2008) B Mosaicplasty (Schewe, 
2008) C Autologous chondrocyte transplantation (ACT) (Marlovits, S. et al., 2006). 
 
 
Mesenchymal stem cells for the repair of cartilage lesions 
The discovery of mesenchymal stem cells (MSCs) and their potential to differentiate 
into cells of the chondrogenic line has opened new potential therapeutic approaches 
for the repair of articular cartilage lesions. The research focus in cartilage repair is 
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currently shifting from using autologous chondrocytes towards the utilization of 
MSCs. MSCs are relatively easy to isolate from different tissues in high quantities, 
MSCs are highly proliferative and can be extensively expanded in an 
undifferentiated status in vitro. MSCs have been transplanted with a view to 
inducing articular cartilage repair in various animal models with promising results 
(Wakitani, S. et al., 1994; Kadiyala, S. et al., 1997; Im, G. I. et al., 2001). In humans 
there are only limited in vivo studies at present. Wakitani et al reported a clinical 
improvement after MSC transplantation and the defect was repaired with 
fibrocartilage and partly hyaline like cartilage (Wakitani, S. et al., 2002). Kudora et al 
reported that after MSC transplantation the cartilage defect was repaired with 
hyaline like cartilage tissue and one year after surgery the clinical symptoms had 
improved significantly (Kuroda, R. et al., 2007). 
1.3 Mesenchymal stem cells (MSCs) 
 MSCs can be isolated from various tissues of the adult body including bone marrow 
(Pittenger, M. F. et al., 1999), adipose tissue (Zuk, P. A. et al., 2001), blood 
(Zvaifler, N. J. et al., 2000) and muscle (Bosch, P. et al., 2000). The most prevalent 
method is the isolation of MSCs from bone marrow aspirates of the iliac crest. MSCs 
can be cultured in vitro in an undifferentiated state and exhibit high proliferative 
activity (Prockop, D. J. et al., 2001). MSCs are multipotent meaning they have the 
ability to differentiate into a variety of different mesenchymal tissues. Dependent on 
the culture conditions and on the growth factors added to the medium, MSCs are 
able to differentiate into bone, cartilage, tendon, muscle, fat, dermis and other 
connective tissues (Prockop, D. J., 1997; Pittenger, M. F. et al., 1999) (Figure 8).  
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Figure 8 Mesenchymal stem cell differentiation. MSCs are able to differentiate into cell types of 
different tissues including bone, cartilage, muscle, marrow and adipose tissue. (Bonfield, T. L. & 
Caplan, A. I., 2010) 
 
 
1.3.1 Chondrogenesis of MSCs 
The chondrogenic potential of MSCs was first described by Owen (Ashton, B. A. et 
al., 1980) and has been characterized in different matrix based and matrix free 
systems (Johnstone, B. et al., 1998; Mackay, A. M. et al., 1998; Yoo, J. U. et al., 
1998; Barry, F. et al., 2001; Noth, U. et al., 2002; Sekiya, I. et al., 2002; Song, L. et 
al., 2004; Ichinose, S. et al., 2005). Johnstone established the classical in vitro 
chondrogenesis model for rabbit bone marrow derived MSCs (Johnstone, B. et al., 
1998). In this model, MSCs differentiate chondrogenically in a pellet culture system 
in a serum free, strictly defined chondrogenic medium containing TGFß, 
dexamethasone, ascorbate, pyruvate, proline and ITS. Based on this model an in 
vitro chondrogenesis model for human MSCs was developed using similar medium 
conditions (Yoo, J. U. et al., 1998). Under these conditions, MSC pellets develop a 
cartilage phenotype, characterized by gene expression and synthesis of collagen 
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type II, collagen type XI, collagen type IX, aggrecan and other chondrogenic specific 
markers (Johnstone, B. et al., 1998; Yoo, J. U. et al., 1998; Pittenger, M. F. et al., 
1999; Barry, F. et al., 2001; Winter, A. et al., 2003).  
1.3.2 Regulation of MSC chondrogenesis 
TGFß1, 2 and 3 are the classical and well established inducers of MSC 
chondrogenesis (Mackay, A. M. et al., 1998; Barry, F. et al., 2001). Although other 
inducers of chondrogenesis such as BMP2 have been described (Schmitt, B. et al., 
2003), this has not been confirmed by other investigators (Winter, A. et al., 2003; 
Indrawattana, N. et al., 2004). FGF2 and IGF promote chondroprogenitor 
proliferation and chondrogenic potential (Mastrogiacomo, M. et al., 2001; Solchaga, 
L. A. et al., 2010). In addition, environmental factors like mechanical stimulation and 
hypoxia have been reported to modulate in vitro chondrogenesis of MSCs (Khan, W. 
S. et al., 2010; Potier, E. et al., 2010).  
1.3.3 Hypertrophy in chondrogenic differentiating MSCs 
Chondrogenic induction of MSCs in pellet culture is accompanied by the up-
regulation of hypertrophy markers like collagen type X and MMP-13 and the 
activation of ALP activity (Johnstone, B. et al., 1998; Yoo, J. U. et al., 1998; Barry, 
F. et al., 2001; Winter, A. et al., 2003; Mwale, F. et al., 2006; Mueller, M. B. & Tuan, 
R. S., 2008; Mueller, M. B. et al., 2010). Expression of collagen type X can be 
detected very early after chondrogenic induction, within 1-2 days, and before 
collagen type II expression is detectable. Furthermore ex vivo transplantation of 
human chondrogenic MSC pellet cultures in mice results in induction of hypertrophy, 
vascular invasion and extensive matrix calcification (Pelttari, K. et al., 2006; Scotti, 
C. et al., 2010). These data suggest that cultured chondrogenic differentiating MSC 
undergo premature hypertrophy and develop into transient endochondral cartilage 
instead of stable articular cartilage. This indicates that the developmental program 
of cultured MSCs resembles that of growth plate chondrocytes rather than that of 
articular chondrocytes. In fact, implanted human articular chondrocytes showed no 
signs of hypertrophy and terminal differentiation (Pelttari, K. et al., 2006) indicating 
that articular chondrocytes are not prone to hypertrophic differentiation and acquire 
an intrinsic and stable arrest before hypertrophy. 
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A recent study from Mueller and Tuan further illustrates the similarity between 
chondrogenic differentiating MSCs and growth plate chondrocytes by demonstrated 
that chondrogenic differentiating MSCs undergo a differentiation program which is 
analogous to that observed during endochondral embryonic skeletal development 
(Mueller, M. B. & Tuan, R. S., 2008). Genes important for chondrogenic 
differentiation and hypertrophy are similarly regulated in MSCs undergoing 
chondrogenic differentiation and growth plate chondrocytes during endochondral 
ossification. Furthermore, the response of chondrogenic differentiating MSCs to 
changing medium conditions is very similar to that of growth plate chondrocytes. 
Thyroid hormone induces hypertrophy while TGFß and dexamethasone inhibit 
hypertrophy (Ballock, R. T. et al., 1993; Leboy, P. S. et al., 1997; Mackay, A. M. et 
al., 1998; Mello, M. A. & Tuan, R. S., 2006; Mueller, M. B. & Tuan, R. S., 2008).  
In order to study the regulation of MSC hypertrophy, an in vitro hypertrophy model 
for MSCs was established (Mackay, A. M. et al., 1998; Mueller, M. B. & Tuan, R. S., 
2008). In this model hypertrophy of MSCs can be enhanced by withdrawal of TGFß 
and dexamethasone and the addition of the thyroid hormone T3 (Figure 9). Under 
these pro-hypertrophic conditions hypertrophy associated markers like collagen type 
X, MMP-13 and osteocalcin are up-regulated and ALP activity is increased 
compared to standard chondrogenic conditions (Mueller, M. B. & Tuan, R. S., 2008).  
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Figure 9 In vitro hypertrophy model. The hypertrophic phenotype of chondrogenic differentiating 
MSCs can be enhanced by the deprivation of TGFß and dexamethasone (Dex) and the addition of 
T3.  
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2 Aim of the study 
Mesechymal stem cells (MSCs) are a promising cell source for the regeneration of 
articular cartilage lesions. MSCs are able to differentiate chondrogenically, however, 
common in vitro protocols for chondrogenesis of MSCs induce an inadequate, 
hypertrophic differentiation cascade that resembles the developmental program of 
growth plate chondrocytes during endochondral ossification. This biological 
behaviour raises concern for a tissue engineering application of MSCs in articular 
cartilage repair. For the use of MSCs in cartilage repair, it is imperative to improve in 
vitro chondrogenesis protocols so that permanent chondrocyte differentiation can be 
induced in the absence of hypertrophy. Therefore it is important to better understand 
the regulation of MSC hypertrophy and find ways to inhibit it. On the other hand, the 
tendency of chondrogenic differentiating MSCs to become hypertrophic might be a 
desirable trait for bone tissue engineering applications. Mechanisms that support 
hypertrophy of MSCs would be favourable for the use of MSCs in bone repair. The 
similarity of MSC chondrogenesis and embryonic endochondral ossification 
suggests that similar mechanisms are involved in the regulation of hypertrophy in 
both biological processes.  
Form studies with growth plate chondrocytes it is known that BMP and TGFß 
signalling regulate terminal differentiation contrarily. BMP signalling promotes and 
TGFß signalling inhibits chondrocyte hypertrophy during endochondral ossification. 
The goal of this thesis was to investigate whether BMP and TGFß signalling are 
involved in the regulation of MSC hypertrophy. We hypothesize, that similar to 
embryonic chondrocytes, BMP signalling promotes hypertrophy and TGFß signalling 
inhibits hypertrophy (Figure 10). In order to investigate this we used an in vitro 
hypertrophy model for chondrogenic differentiating MSCs in which the hypertrophic 
phenotype can be strongly enhanced by modulations in the medium conditions.  
Differential expression analysis of BMP and TGFß signalling associated genes 
including ligands, receptors, transcription factors between chondrogenic and 
hypertrophic MSC cultures was carried out. BMP and TGFß signalling activity 
between chondrogenic and hypertrophic MSC cultures was compared. Functional 
experiments with modulations of BMP and TGFß activity were carried out.  
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Figure 10 Hypothesis: BMP and TGFß signalling promote early chondrogenic differentiation stages 
of MSCs while terminal differentiation is positively regulated by BMP signalling and negatively 
regulated by TGFß signalling.  
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3 Material and Methods 
3.1 Material 
3.1.1 Recombinant Proteins and Inhibitors 
 
chemical application concentration company 
BMP4 BMP ligand 100 ng/ml R&D 
systems 
dorsomorphin Inhibitor of BMP signalling: 
selective inhibitor of BMP 
type I receptor 
0,5 µM, 3 µM, 10 µM Sigma 
Aldrich 
noggin Inhibitor of BMP signalling: 
antagonist of BMPs 
10 ng/ml, 100 ng/ml R&D 
systems 
SB431542 Inhibitor of TGFß signalling: 
selective inhibitor of TGFß 
type I receptor  
0,5 µM, 3 µM, 10 µM Tocris 
TGFß1 TGFß ligand 10 ng/ml R&D 
systems 
Table 1 Recombinant Proteins and Inhibitors 
 
 
3.1.2 Primers 
Primers were synthesized by eurofins, purified and lyophilized. Stock solutions of 
100 μM (100 pmol/μl) were prepared and stored at -80°C. The following primers 
were used. 
 
gene sequence (forward) sequence (reverse) concen-
tration 
Alk2 GCCTGGAGCATTGGTAA
GC 
 
CTGCCCACAGTCCTTCAA
G 
 
150 nM 
BAMBI CGATGTTCTCTCTCCTCC
CAG 
 
AATCAGCCCTCCAGCAAT
GG 
 
150 nM 
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BMP2 
 
TGGATTCGTGGTGGAAG
TGGC 
 
AGGGCATTCTCCGTGGC
AGTA 
 
200 nM 
BMP4 CAAACTTGCTGGAAAGG
CTC 
 
CCGCTACTGCAGGGACC
TAT 
 
200 nM 
BMP7 CCCAGTGTTTACCGAGGT
TTGC 
TCCATCCTACTTGCTGTC
CTTGTC 
200 nM 
BMPR1A  AAACCACTTCCAGCCCTA
C 
 
TTTGACACACACAACCTC
AC 
 
200 nM 
BMPR1B  
 
CCCTGCATTTGGGGCCG
CTAT 
 
GCCTGAAGCTGCAAAAG
GCCAC 
 
200 nM 
BMPR2  
 
CCAAGGTCTTGCTGATAC
GG 
 
CTACCATGGACCATCCTG
CT 
 
200 nM 
Chordin CTGCAGCAGCATATGAG
CC 
GATCAGCGCACTGTCCT
GT 
200 nM 
Collagen 
type II 
GGGCAATAGCAGGTTCA
CGTA 
 
TGTTTCGTGCAGCCATCC
T 
 
200 nM 
Collagen 
type X 
CCCTCTTGTTAGTGCCAA
CC 
 
AGATTCCAGTCCTTGGGT
CA 
 
200 nM 
Follistatin TCCTTGCTCAGTTCGGTC
TT 
TCTGCCAGTTCATGGAG
GA 
200 nM 
Gremlin CAGGGAAAGCTTCCAGA
ACA 
CCCGCTGTGGACTAGAG
AAC 
200 nM 
HPRT 
 
CGAGATGTGATGAAGGA
GATGG 
 
GCAGGTCAGCAAAGAATT
TATAGC 
 
150 nM 
Noggin CATGAAGCCTGGGTCGT
AGT 
 
TGGAACACCCAGACCCT
ATC 
 
200 nM 
Osteocalci
n 
AGGAGGGCAGCGAGGTA
G 
GAAAGCCGATGTGGTCA
GC 
100 nM 
Runx2 
 
ATACCGAGTGACTTTAGG
GATGC 
 
AGTGAGGGTGGAGGGAA
GAAG 
 
200 nM 
Sox9 ACACACAGCTCACTCGAC
CTTG 
 
AGGGAATTCTGGTTGGTC
CTCT 
 
200 nM 
TGFß1 ACATCAACGGGTTCACTA
C 
 
CTGAAGCAATAGTTGGTG
TCC 
 
200 nM 
TGFß3 ACACACAAGCAACAAACC
TCAC 
 
AACCAAACCCACACTTTC
TTTACC 
 
200 nM 
TGFßR1 GAACCTGCTCTCCTGCTT
G 
 
GCCTCATCTGCTCAATCT
CC 
 
200 nM 
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TGFßR2 GGAAACTTGACTGCACC
GTT 
 
CTGCACATCGTCCTGTG
G 
 
200 nM 
Table 2 List of Primers  
 
 
3.1.3 Antibodies 
 
Primary antibodies 
Antibody dilution company 
BAMBI (mouse) 1:1000 (WB) 
1:10 (IH) 
eBioscience 
Sox9 (mouse) 1:500 Millipore 
Smad 1 (rabbit) 1:1000 Cell signalling 
phospho-Smad 1,5 (rabbit) 1:500 Cell signalling 
Smad 2 (rabbit) 1:1000 Cell signalling 
phospho-Smad 2 (rabbit) 1:1000 Cell signalling 
Smad 3 (rabbit) 1:1000 Cell signalling 
phospho-Smad 3 (rabbit) 1:1000 Cell signalling 
TGFßR1 (rabbit) 1:500 Abcam 
ß-Actin (rabbit) 1:10000 Abcam 
BMP4 (rabbit) 1:250 Abcam 
Collagen type II (mouse) 1:100 Calbiochem 
Collagen type X (mouse) 1:20 Quartett 
Immunodiagnostica 
Secondary antibodies 
goat-anti-mouse (biotinylated) 1:100 Dianova 
goat-anti-rabbit (biotinylated) 1:100 Dianova 
goat-anti-mouse (HRP- conjugated) 1:1000 Pierce 
goat-anti-rabbit (HRP-conjugated) 1:1000 Pierce 
Table 3 List of antibodies 
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3.1.4 Kits 
 
name application  company 
Alkaline Phosphatase Kit ALP staining Sigma Aldrich  
Brilliant SYBR Green QPCR 
Master Mix 
qPCR  Agilent 
Technologies 
DC Protein Assay Protein concentration Biorad 
DNA-free DNase treatment 
and removal 
DNA digestion Ambion by life 
technologies 
ECL western kit Western Blot pierce 
Re-blot Plus Stripping of Western Blot 
membranes 
Millipore 
RNeasy Mini Kit  RNA clean up, DNA digestion  quiagen 
Transcriptor First Strand cDNA 
Synthesis 
cDNA synthesis Roche 
Table 4 List of Kits 
 
 
3.1.5 Buffers and solutions 
Running Buffer  
50 mM MOPS 
50 mM Tris base 
0,1 % SDS 
1 mM EDTA 
 
Transfer Buffer  
25 mM Bicine 
25 mM Bis tris free base 
1 mM EDTA 
20 % methanol 
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Tris 0,2 M (ph 7,0) 
24,2 g Tris base  
add H2O to 1l 
 
Washing Buffer 
780 ml Tris 0,2 M (ph 7,0) 
25 g NaCl 
add H2O to 3 l 
 
Blocking Buffer 
120 ml Tris 0,2 M (ph 7,0) 
2,4 g NaCl 
60 ml Triton X100 
1% FCS 
1% goat serum 
add H2O to 250 ml  
 
PBS 
137 mM NaCl 
2,7 mM KCl 
10 mM Na2HPO4 x 2 H2O 
2 mM KH2PO 
 
Phosphate-Buffer (0.2 M) 
29,7 g Na2HPO4 
4,6 g NaH2PO4  
add H2O to 1 l 
 
TBS  
25 mM Tris/HCl (pH 7,5) 
150 mM NaCl 
 
TBST 
0,1 % Tween 20 in TBS 
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ALP Buffer 
1,5 M Tris (ph 9,0) 
1 mM MgCl 
1 mM ZnCl 
3.1.6 Cells 
Human mesenchmyal stem cells (MSCs) derived from the iliac crest of male 
patients aged 21 to 42 (n=10) were used for the experiments.  
3.1.7 Cell culture media 
Proliferation medium:  
Dulbecco’s modified Eagle’s medium (DMEM) low glucose (Invitrogen) with 10 % 
fetal calf serum (PAN Biotech GmbH) and 1 % penicillin/streptomycin (Invitrogen). 
Differentiation medium:  
Chondrogenic medium: DMEM high glucose (Invitrogen), 1 % ITS+3 (Sigma 
Aldrich), 50 μg/ml ascorbate-2-phosphate (Sigma Aldrich), 40 μg/ml L-proline 
(Sigma Aldrich), 100 nM dexamethasone (Sigma Aldrich), 1 mM sodium pyruvate 
(Sigma Aldrich) and 10 ng/ml TGFß1 (R&D Systems). 
Hypertrophy enhancing medium: DMEM high glucose, 1 % ITS+3, 50 µg/ml 
ascorbate-2-phosphate, 40 µg/ml L-proline, 1 nM triiodothyronine (T3) (Sigma 
Aldrich). 
3.2 Methods 
3.2.1 Cell culture 
3.2.1.1 Isolation of MSCs 
Human MSCs were isolated from iliac crest bone marrow aspirates of male patients 
undergoing surgery that required autologous bone grafting with approval of the 
ethics committee of the University of Regensburg and written consent. MSCs were 
isolated by Ficoll gradient centrifugation as described previously (Haynesworth et al, 
1992). Therefore bone marrow was mixed 1:5 with proliferation medium (as 
indicated in 3.1.7). Afterwards the bone marrow medium mixture was carefully 
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layered onto a Ficoll (Biochrom) cushion in a 50 ml Falcon tube. The Falcon tube 
was then centrifuged for 35 minutes at 1680 U/min. The nucleated cell fraction, in 
which MSCs are located, was collected from the 1,077 g/ml density interface and 
mixed with fresh proliferation medium. After a further centrifugation step (10 min, 
1000 U/min), the pellet was resuspended in fresh medium, the cell number was 
determined and the cells were plated at a density of 2 million cells per 75 cm2 tissue 
culture flasks.  
 
 
 
Figure 11 Isolation of MSCs. A Bone marrow aspiration from the iliac crest. 
(http://www.mayoclinic.com/images/image_popup/r7_bonemarrowaspiration.jpg) B Ficoll gradient 
(P=plasma, M=mononuclear cells, F=ficoll, R=erythrocytes, thrombocytes). MSCs are located in the 
mononuclear layer. (www.umfacts.um.edu.my). C Monolayer culture of MSCs 
 
 
3.2.1.2 Expansion of MSCs 
MSCs were cultured as monolayer in 15 ml proliferation medium in 75 cm2 tissue 
culture flasks. Cells were maintained at 37 °C in a humified atmosphere containing 5 
% CO2. Medium changes were performed every three to four days and at 80 % 
confluence cells were trypsinized and frozen for later use in liquid nitrogen.  
3.2.1.3 Chondrogenic differentiation and enhancement of hypertrophy 
For chondrogenic differentiation of the MSCs, the in vitro chondrogenesis model 
established by Johnstone et al (Johnstone, B. et al., 1998) was used. MSCs of 
passage two were used for the experiments.  
MSCs were thawed, seeded in 75 cm2 tissue flasks and expanded in proliferation 
medium until confluence was reached. Cells were washed with sterile PBS (PAA), 3 
ml trypsin (PAN Biotech GmbH) was added and tissue flasks were softly shacked, 
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until the cells detached from the surface. Cells were resuspended in fresh 
proliferation medium to inactivate the trypsin and then centrifuged for 5 minutes at 
1000 U/min. The pellet was resuspended in DMEM high glucose medium, cell 
number was determined and 200000 cells per well were seeded in V-bottomed 96-
well polypropylene plates. Pellets were formed by centrifugation at 250 g for 5 
minutes and chondrogenically differentiated in chondrogenic medium (as indicated 
in 3.1.7) for 14 days. After the chondrogenic pre-differentiation phase, pellets either 
stayed in chondrogenic medium for another 14 days or were transferred to 
hypertrophy enhancing medium (as indicated in 3.1.7).  
MSC pellets were maintained at 37 °C in a humified atmosphere containing 5 % 
CO2. Medium was changed three times per week. MSC pellets were isolated at 
different time points (as indicated in the respective section), characterized 
histologically, histochemically and immunohistochemically and gene expression and 
protein expression were analyzed. 
 
 
 
Figure 12 Paradigm. For expansion of MSCs, cells were kept in proliferation medium for about 10 
days. Then cells were transferred to pellet culture system and pre-differentated in chondrogenic 
medium for 14 days. Afterwards pellets either stayed in chondrogenic medium or were transferred to 
hypertrophic medium for additional 14 days. 
 
 
3.2.1.4 Modulation of hypertrophy  
Modulation of hypertrophy by BMP4  
MSC aggregates were formed as described and were kept in chondrogenic medium 
for 14 days. Then aggregates were distributed in five different groups: 1. standard 
chondrogenic medium; 2. chondrogenic medium with BMP4, 3. standard 
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hypertrophy enhancing medium including T3; 4. hypertrophy enhancing medium 
without T3; 5. hypertrophy enhancing medium with BMP4 instead of T3. (BMP4 was 
used in the concentration as described in table 1). 
Aggregates for gene expression analysis were harvested on day 21 and day 28. For 
histological analysis aggregates were harvested on day 28 and medium supernatant 
was isolated on day 28 for ALP activity test. 
Modulation of hypertrophy by BMP and TGFß inhibitors 
MSC aggregates were formed as described and were kept in chondrogenic medium 
for 14 days. On day 14, aggregates were either kept in chondrogenic medium with 
noggin, dorsomorphin or SB431542 or were transferred to hypertrophic medium with 
noggin, dorsomorphin or SB431542 for additional 14 days (inhibitors were used in 
the concentrations as described in table 1). MSC pellets that were kept in standard 
chondrogenic and hypertrophic medium were taken as control.  
Aggregates were harvested for gene expression analysis on day 21 and day 28 and 
for histological analysis on day 28. Culture medium was collected on day 28 for 
determination of ALP activity. 
In a separate approach MSC pellets were treated with noggin or dorsomorphin over 
the whole culture period, from day 1 until day 28, or treated with dorsomorphin from 
day 1 until day 14. MSC pellets were harvested on day 28 for histological analysis. 
In another experiment MSC pellets were pre-differentiated in chondrogenic medium 
for 14 days followed by incubation in chondrogenic medium containing BMP4 and 
SB431542. MSC pellets were harvested on day 14 and day 28 for histological 
analysis. 
The noggin experiment was done in collaboration with a medical PhD student, 
Norman Olbrich. The results from the PCR, ALP activity and cell size measurement 
comprise data derived from Norman Olbrich and data from me.  
3.2.2 Histology, Histochemistry and Immunohistochemistry 
3.2.2.1 Fixation of MSC pellets and preparation of cryo sections 
For histological, histochemical and immunohistochemical analysis, MSC pellets 
were harvested on day 14 and day 28 and fixed in 4 % paraformaldehyde for 1 hour. 
Afterwards pellets were washed in 0,1 M phosphate buffer for 1 hour followed by 
incubation in saccherose solutions with increasing concentrations (10 %, 20 %, 30 
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% saccherose solution in 0,1 M phosphate buffer), each for 1 hour. Then MSC 
pellets were embedded in TissueTek (Sakura) and frozen in liquid nitrogen. 10 µm 
thick frozen sections were prepared using the Microm HM 500 OM Cryotom 
(Microm, Berlin, Deutschland). 
3.2.2.2 DMMB staining  
DMMB (1,9-dimethylmethylenblue) stains sulphated glycosaminoglycans (GAGs) 
that are synthesized during chondrogenic differentiation. Cryo sections were 
incubated in tip water for 5 minutes followed by incubation in 0,1 % DMMB solution 
(Sigma Aldrich) for 5 to 10 minutes. Then sections were washed in tip water (2x 1 
minute) and dehydrated (2x 100 % Propanol; 2x 100 % Xylol, 5 minutes each). 
Cover slips were mounted on slides with DePex-solution (Serva Electrophoresis 
GmbH) and afterwards investigated under the microscope.  
3.2.2.3 Alkaline phosphatase (ALP) staining 
ALP staining was performed using an alkaline phosphatase kit (Sigma Aldrich) 
according to manufacturer’s instructions. Neutral red was used as counterstaining. 
Cover slips were mounted on slides with 70 % sorbitum solution (Caelo) and 
afterwards investigated under the microscope.  
3.2.2.4 Immunohistochemistry 
Sections were incubated in washing buffer for 5 minutes. Afterwards endogen 
peptidases were blocked in 3 % H2O2/10 % Methanol in PBS for 30 minutes. 
Sections were washed three times in washing buffer, followed by incubated in 
blocking buffer for 60 minutes at room temperature and incubation in appropriate 
primary antibody in blocking buffer overnight at room temperature. For collagen type 
II and type X staining antigen retrieval with pepsin digestion for 15 minutes at room 
temperature was performed prior to blocking. For collagen type X staining additional 
hyaluronidase digestion for 60 minutes at room temperature was performed prior to 
pepsin digestion. Immunolabeling was detected with a biotinylated secondary 
antibody, horse reddish peroxidase conjugated streptavidin (Vector Laboratories, 
Burlingame) and metal enhanced diaminobenzidine as substrate (Sigma Aldrich). 
3.2.3 Microscopy 
The following microscopes were used: Olympus BX 61, Nicon Eclipse TE2000-U. 
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3.2.4 Histomorphometry 
Day 28 aggregates were stained with DMMB and images of three representative 
central sections were taken in 20 x magnification. The surface area of the cells in 
the sections was analyzed as correlate of the cell size using the Image J software 
(NIH, Bethesda, MD). Per condition three aggregates from five different patients 
were analyzed.  
3.2.5 Determination of Alkaline Phosphatase (ALP) activity  
ALP activity in the medium was measured densitometrically using the change in the 
absorbance at 405 nm by the conversion of p-nitrophenyl phosphate to p-
nitrophenol and inorganic phosphate as described previously (Weber, M. et al., 
2002). Medium supernatant was harvested on day 28 and centrifuged for 5 minutes 
at maximum speed. 100 μl of supernatant was added to 100 µl substrate solution (4 
mg/ml p-nitrophenol phosphate (Sigma Aldrich) in ALP buffer) and continuous 
absorbance at 405 nm was measured spectrophotometrically in a microplate reader 
at room temperature (Genius plate reader, Tecan). The change in A405 over time 
(dA/min) was calculated in the linear range of the reaction.  
3.2.6 Gene expression analysis 
3.2.6.1 RNA isolation and cDNA synthesis 
For gene expression analysis RNA was isolated from MSC aggregates at day 1, day 
3, day 7, day 14, day 17, day 21 and day 28. 8 to 10 pellets per condition and per 
time point for each donor were pooled, incubated in 1 ml TRI Reagent (Sigmal 
Aldrich) and homogenized using the Power Gen 1000 homogenizator (Fischer 
Scientific). RNA was isolated using standard protocols for Trizol isolation. Briefly, 
200 µl Chloroform was added to the lysate and the solution was shacked for 15 
seconds, incubated at room temperature for 15 minutes and centrifuged for 15 
minutes at 12000 g at 4 °C. The aqueous phase was then transferred to a new tube 
and precipitated with 400 µl Isopropanol. After centrifugation (12000 g, 10 minutes, 
4 °C) the obtained RNA pellet was washed with 75 % Ethanol and centrifuged (7500 
g, 8 minutes, 4 °C). RNA pellet was dried for 30 minutes at room temperature and 
was afterwards dissolved in 20 µl RNase free water. Residual DNA was digested 
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using the DNA-free DNase treatment & removal kit (ambion by life technologies) 
according to manufacturer’s instructions. RNA concentration was measured using 
the Picodrop analyzer (Biozym). 1 µg RNA was reverse transcribed in cDNA with 
the Transcriptor First Strand cDNA Synthesis kit (Roche) according to 
manufacturer’s instructions.  
3.2.6.2 Real time polymerase chain reaction (PCR) 
Gene expression analysis was performed with semiquantitative real-time PCR using 
Brilliant SYBR Green QPCR Master Mix (Agilent Technologies) and the CFX96 Real 
time PCR Detection System (Biorad). The optimal concentration of the primers was 
tested out for each primer and is listed together with the sequences in table 2. cDNA 
was diluted to a concentration of 1 ng/µl and the PCR reaction was performed in a 
final volume of 15 µl containing 7,5 µl Brilliant SYBR Green QPCR mix, 1,5 µl primer 
mix, 1,5 µl DEPC water and 5 µl cDNA. The following PCR conditions were used. 
An initial denaturation step at 95°C for 15 minutes was followed by 40 cycles of 
denaturation at 95°C for 10 seconds and primer annealing and extension at 60°C for 
30 seconds. Melt curve analysis was performed by slowly heating the PCR reaction 
from 55°C to 95°C (0,5°C per cycle) with simultaneous measurement of fluorescent 
intensity. 
Gene expression was normalized to the housekeeping gene, hypoxanthine guanine 
phosphoribosyltransferase (HPRT).  
3.2.7 Protein analysis 
3.2.7.1 Western Blot analysis 
For Western Blot analysis 5 to 8 MSC pellets per time point and per condition for 
each patient were pooled, washed in ice cold PBS and homogenized in 500 μl 6 M 
urea/2 % SDS solution containing protease inhibitor cocktail (Sigma) and 
phosphatase inhibitor (Sigma) using the Power Gen 1000 homogenizator (Fischer 
Scientific). The lysate was centrifuged for 5 minutes at 14000 rpm (4 °C) to pellet 
cellular debris and the supernatant was transferred to a fresh tube. The protein 
concentration of the supernatant was determined using the BCA Protein Assay kit 
(Biorad, DC Protein Assay) according to the manufacturer´s instructions. 
Lysates were supplemented with 4x LDS sample buffer (Invitrogen) and 10 mM 
dithiothreitol (DTT) and proteins were denaturated for 5 minutes at 95 °C. For gel 
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electrophoresis, equal amounts of protein (10 μg) were loaded and separated on a 
4-12 % bis tris gel (novex by life technologies) at 120 V. After gel electrophoresis 
proteins were transferred from the gel to a polyvinylidenfluoride (PVDF) membrane 
(millipore). Blotting was performed for 2 hours at 100 V. After transfer, membrane 
was blocked for 1 hour in 5 % skim milk powder in TBST. The membrane was then 
incubated in primary antibody in 5 % skin milk powder in TBST over night at 4 °C. 
The next day, the membrane was washed three times for 10 minutes in TBST and 
afterwards incubated in HPR-coupled secondary antibody (1:1000) in 5 % skin milk 
powder in TBST at room temperature for 1 hour. The membrane was washed three 
times in TBST for 10 minutes. Chemoluninescence was detected with the ECL 
western kit (pierce) and by using x-ray sensitive films (ECL Hyperfilm, Amersham). 
The films were developed in a photo developer (Curix 60) from AGFA. 
Western Blot membranes were stripped using Re-blot Plus (Millipore) according to 
manufactures instructions.  
3.2.8 Microarray 
RNA was isolated as described. Afterwards RNA was cleaned up and residual DNA 
was digested using the RNeasy Mini Kit (quiagen). The samples were analysed by 
the Kompetenzzentrum für Fluoreszente Bioanalytik Microarray Technology (KFB) 
using the Affymetrix GeneChip Analysis.   
3.2.9 Statistical analysis 
The data from the real time-PCR analysis, ALP activity test and cell surface area 
analysis were expressed as mean values ± standard deviation (SD). Each 
experiment was carried out using cells of four to seven individual marrow 
preparations from different donors, as indicated in the respective experiments. 
Statistical analysis was carried out by pair-wise comparison using paired, 2-tailed 
student´s t-test in SigmaStat software (Jandel Scientific, San Rafael, CA). A level of 
p<0.05 was considered significant.  
Results  
43 
4 Results 
4.1 Characterization of MSC pellets under chondrogenic and 
hypertrophic conditions 
Using an in vitro hypertrophy model for MSCs we compared MSC pellets that were 
kept under chondrogenic and hypertrophic conditions histologically and on gene 
expression level.  
4.1.1 Histological analysis 
The hypertrophic phenotype of chondrogenic differentiating MSCs is strongly 
enhanced under hypertrophic medium conditions compared to chondrogenic 
conditions. Histological analysis of day 28 aggregates revealed that aggregates that 
were kept under hypertrophy enhancing conditions clearly showed hypertrophic cell 
morphology with large lacunae typical for hypertrophic cartilage (Figure 13 B) 
whereas chondrogenic control aggregates showed a more hyaline cartilage-like 
morphology with little sign of cellular hypertrophy (Figure 13 A). Collagen type II 
staining is strong both under chondrogenic (Figure 13 C) and hypertrophic 
conditions (Figure 13 D). In contrast, immunostaining for the hypertrophic marker 
collagen type X is weak in chondrogenic aggregates (Figure 13 E) but is clearly 
increased in hypertrophic MSC pellets (Figure 13 F). ALP staining is strong 
throughout the aggregates under pro-hypertrophic conditions (Figure 13 H) whereas 
ALP staining is weaker and mainly located in the periphery in chondrogenic 
aggregates (Figure 13 G). 
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Figure 13 Histological appearance of MSC pellets on culture day 28 under chondrogenic (A, C, 
E, G) and hypertrophy enhancing conditions (B, D, F, H). A, B DMMB staining. C, D 
immunohistochemical collagen type II staining. E, F immunohistochemical collagen type X staining. 
G, H alkaline phosphatase (ALP) staining (blue) with neutral red as counterstaining. The hypertrophic 
phenotype with increased cell volume, collagen type X expression and ALP activity is strongly 
enhanced under hypertrophy enhancing conditions (B, D, F, H) compared to chondrogenic conditions 
(A, C, E, G). Scale bar = 500µm.  
 
 
4.1.2 Gene expression analysis 
Furthermore we analyzed the gene expression of the chondrogenic marker collagen 
type II and the hypertrophic markers collagen type X and osteocalcin comparatively 
between chondrogenic and hypertrophic MSC pellets.  
Real time PCR analysis revealed that collagen type II expression increases over 
time both under chondrogenic and hypertrophic conditions. However no significant 
difference can be detected in the expression of collagen type II between 
chondrogenic and hypertrophic pellets (Figure 14 A). Collagen type X expression 
also increases over time but in contrast to the immunostaining for collagen type X, 
no significant difference in collagen type X expression can be detected in the PCR 
between chondrogenic and hypertrophic condition (Figure 14 B). MSC pellets that 
were kept under standard chondrogenic conditions express a high level of the 
hypertrophic marker collagen type X. Osteocalcin is a bone specific marker that is 
expressed by osteoblasts but has also been shown to be up-regulated in 
hypertrophic chondrocytes (Lian, J. B. et al., 1993; Gerstenfeld, L. C. & Shapiro, F. 
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D., 1996). Gene expression analysis for osteocalcin revealed a significant 
enhancement in osteocalcin expression under hypertrophic conditions on day 17, 
day 21 and day 28 compared to chondrogenic conditions (Figure 14 C).  
 
 
 
Figure 14 Gene expression analysis of collagen type II, collagen type X and osteocalcin 
normalized to HPRT in MSC pellet cultures under chondrogenic and hypertrophy enhancing 
conditions analyzed by real time PCR. Collagen type II and collagen type X expression increases 
over time with no significant difference between chondrogenic and hypertrophic conditions (A, B). 
Osteocalcin expression is significantly increased under hypertrophic conditions compared to 
chondrogenic conditions (C). n= 7 different donors. 
 
 
These experiments clearly showed that we can increase hypertrophy of 
chondrogenic differentiating MSCs by switching medium conditions from 
chondrogenic to hypertrophic medium.  
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4.2  The role of BMP signalling in the induction of hypertrophy in 
chondrogenic differentiating MSCs 
BMP signalling has been shown to promote hypertrophy in growth plate 
chondrocytes (1.1.1.1). In the following part we aimed to investigate whether BMP 
signalling is also involved in the regulation of MSC hypertrophy.  
4.2.1 Regulation of BMP signalling associated genes under 
hypertrophy enhancing conditions 
In order to elucidate a possible role of BMP signalling in the regulation of MSC 
terminal differentiation we compared temporal expression profiles of genes involved 
in BMP signalling (ligands, receptors, transcription factors) between chondrogenic 
and hypertrophic MSC pellets.  
Real time PCR analysis showed that BMP4 is significantly up-regulated under 
hypertrophy enhancing conditions on day 17, day 21 and day 28 as compared to 
chondrogenic control conditions (Figure 15 A). Differences in BMP2 expression 
between chondrogenic and hypertrophic conditions were not detected (Figure 15 B). 
BMP7 expression was too low both in chondrogenic and hypertrophic aggregates to 
evaluate differences between the two conditions. The BMP receptor 1B (BMPR1B) 
is significantly up-regulated in the hypertrophic group on day 28 compared to the 
chondrogenic group (Figure 15 C). All other investigated BMP receptors (BMPR1A, 
Alk2, BMPR2) were not regulated as a function of hypertrophy induction (data not 
shown). The BMP signalling associated transcription factor Runx2 is significantly up-
regulated on day 17, day 21 and day 28 under pro-hypertrophic conditions (Figure 
15 D).  
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Figure 15 Gene expression analysis of BMP4, BMP2, BMPR1B and Runx2 normalized to HPRT 
in MSC pellet cultures under chondrogenic and hypertrophy enhancing conditions analyzed 
by real time PCR. BMP4 and Runx2 are significantly up-regulated on day 17, 21 and 28 under 
hypertrophic conditions (A, D). BMPR1B is up-regulated on day 28 under hypertrophic conditions (C) 
BMP2 is not regulated as a function of hypertrophy (B). n = 7 different donors.  
 
 
On protein level, immunohistochemistry for BMP4 on day 28 showed clearly 
stronger staining in hypertrophic MSC pellets (Figure 16 B, D) compared to 
chondrogenic pellets (Figure 16 A, C). BMP4 predominantly accumulates in the 
membrane and cytoplasm of hypertrophic cells (Figure 16 D), whereas BMP4 
staining in chondrogenic aggregates is weak in the membrane and the cytoplasm of 
chondrogenic cells (Figure 16 C).  
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Figure 16 Immunohistochemical BMP4 staining of day 28 MSC pellets. BMP4 protein staining is 
increased under hypertrophy enhancing conditions (B, D) as compared to chondrogenic conditions 
(A, C). Scale bar = 100 µm. 
 
 
4.2.2 BMP4 induces hypertrophy 
The previous results showed that BMP4 expression is strongly enhanced under 
hypertrophic conditions. Therefore we aimed to analyse the effect of recombinant 
human BMP4 on chondrogenic differentiating MSCs in the in vitro hypertrophy 
model. 
4.2.2.1 Histological analysis 
Under standard chondrogenic conditions (chon) with continuous application of TGFß 
and dexamethasone, BMP4 application (chon+BMP4) did not trigger changes in the 
phenotype of chondrifying MSCs. Under both conditions, a similar hyaline cartilage-
like morphology with little signs of hypertrophy developed (Figure 17 A, B). No 
difference in ALP staining could be detected between BMP4 treated and 
chondrogenic control aggregates (Figure 17 C, D). In addition collagen type II and 
collagen type X immunostaining were unchanged after BMP4 treatment (Figure 17 
E, F, G, H).  
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Figure 17 Histological appearance of MSC pellets on day 28 after BMP4 treatment under 
chondrogenic conditions. A, C, E, G chondrogenic control conditions. B, D, F, H BMP4 treated 
conditions. No change in DMMB (A, B), ALP (C, D), Collagen type II (E, F) and collagen type X (G, 
H) staining can be detected between chondrogenic control conditions and BMP4 treated conditions. 
Scale bar = 200 µm.  
 
 
The change to standard pro-hypertrophic medium conditions with addition of T3 and 
withdrawal of TGFß and dexamethasone (hyp) resulted in a hypertrophic phenotype 
with increased cell size, ALP positivity and increased collagen type X staining 
(Figure 18 A, D, J). In aggregates that were incubated in medium without TGFß and 
dexamethasone but without addition of T3 (hyp-T3), cell size, ALP and collagen type 
X staining were increased compared to the regular chondrogenic control but all 
parameters were clearly less enhanced than in standard hypertrophic cultures that 
received T3 (Figure 18 B, E, K). After withdrawal of TGFß and dexamethasone and 
the addition of BMP4 instead of T3 (hyp-T3+BMP), the aggregates developed a very 
strong hypertrophic phenotype with larger cells compared to all other groups, strong 
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ALP and collagen type X staining (Figure 18 C, F, L). Furthermore collagen type II 
staining seems to be enhanced in BMP4 treated MSC pellets compared to 
hypertrophic medium with and without T3 (Figure 18 G, H, I). 
 
 
 
Figure 18 Histological appearance of MSC pellets on day 28 after BMP4 treatment under 
hypertrophic conditions. A, D, G, J hypertrophic standard medium. B, E, H, K hypertrophic 
medium without T3. C, F, I, L hypertrophic medium without T3 but with BMP4. Cell size (A, B, C), 
ALP staining (D, E, F), collagen type II (G, H, I) and collagen type X (J, K, L) staining are increased 
after BMP4 treatment (C, F, I, L) compared to hypertrophic medium with (A, D, G, J) and without T3 
(B, E, H, K). Scale bar = 200 µm.  
 
 
4.2.2.2 Histomorphometry 
Histological analysis indicated that the cell size of MSC pellets increased after 
BMP4 treatment under hypertrophic conditions. In order to confirm this, we 
performed a histomorphometric cell size analysis of day 28 aggregates. 
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Under chondrogenic medium conditions histomorphometric analysis did not identify 
significant differences in the cell size between chondrogenic control aggregates and 
BMP4 treated aggregates. Histomorphometry detected significantly increased cell 
size under standard hypertrophic conditions compared to standard chondrogenic 
conditions. Furthermore, cells were significantly larger in aggregates in hypertrophic 
medium with T3 compared to hypertrophic medium without T3. Cells in pellets that 
were incubated in hypertrophic medium with BMP4 were significantly larger than 
cells cultured under any other condition (Figure 19 A). 
Figure B shows the distribution of the cell size representative for one patient (Figure 
19 B). 
 
 
 
Figure 19 Histomorphometric cell size analysis of MSC pellets on day 28 after BMP4 
treatment. A Under chondrogenic conditions BMP4 treatment has no influence on the cell size. 
Under hypertrophic conditions withdraw of T3 (hyp-T3) significantly reduces the cell size compared to 
hypertrophic standard conditions with T3 (hyp). Cell size of aggregates treated with BMP (hyp-
T3+BMP) is significantly increased compared to hypertrophic medium with and without T3. n = 5 
different donors. B distribution of the cell size representative for one patient.  
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4.2.2.3 ALP activity in the medium supernatant 
Analysis of ALP activity in the medium of day 28 pellets under hypertrophic 
conditions revealed that ALP activity is significantly increased in pellets that were 
incubated in hypertrophic medium with T3 compared to hypertrophic medium 
without T3. ALP activity is significantly increased in the medium of pellets treated 
with BMP4 compared to pellets that were incubated in hypertrophic medium with 
and without T3 (Figure 20).  
 
 
 
Figure 20 ALP activity in the medium of day 28 MSC pellets after BMP4 treatment under 
hypertrophic conditions. ALP activity in the medium with T3 (hyp) is significantly increased 
compared to medium without T3 (hyp-T3). BMP4 significantly increases ALP activity compared to 
hypertrophic medium with and without T3. n=7 different donors. 
 
 
4.2.2.4 Gene expression analysis 
To further characterize the effect of BMP4 on chondrogenic differentiating MSCs, 
gene expression of collagen type II, collagen type X and BMP4 was analysed in 
MSC pellets on day 21 and day 28 after BMP4 treatment. 
Under chondrogenic conditions, the addition of BMP4 did not significantly affect 
collagen type II expression. Under pro-hypertrophic conditions, BMP4 treatment 
significantly increased collagen type II expression compared to hypertrophic 
conditions with and without T3 on day 21 and day 28 (Figure 21 A). Collagen type X 
expression was not affected by BMP4 treatment under chondrogenic conditions. 
Under hypertrophy enhancing conditions collagen type X expression was 
significantly increased in BMP4 treated aggregates compared to hypertrophic 
aggregates with and without T3 (Figure 21 B). 
Histology, histomorphometry and ALP activity in the medium pointed out that in 
hypertrophic medium without T3 there is a less enhanced hypertrophic phenotype 
compared to hypertrophic medium with T3. It is important to investigate if there are 
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also differences in the BMP4 expression between these two conditions. Real time 
PCR analysis revealed that BMP4 expression is significantly increased in MSC 
pellets in hypertrophic medium with T3 compared to hypertrophic medium without 
T3 on day 21 and day 28. Furthermore the exogenous addition of BMP4 to the 
medium significantly suppresses BMP4 expression (Figure 21C). 
 
 
 
Figure 21 Gene expression analysis of collagen type II, collagen type X and BMP4 normalized 
to HPRT in MSC pellet cultures after BMP4 treatment under chondrogenic (chon) and 
hypertrophy enhancing (hyp) conditions analyzed by real time PCR. Collagen type II and 
collagen type X expression is significantly increased after BMP4 treatment under hypertrophic but not 
under chondrogenic conditions (A, B). BMP4 expression is significantly increased in MSC pellets 
incubated in hypertrophic medium with T3 (hyp) compared to hypertrophic medium without T3 (hyp-
T3) on day 21 and day 28 (C). n = 4 different donors.  
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4.2.3 The BMP inhibitor noggin inhibits thyroid hormone induced 
hypertrophy 
Previous results showed that BMP4 is able to further increase hypertrophy of 
chondrogenic differentiating MSCs under hypertrophic conditions. Next we aimed to 
investigate whether the BMP inhibitor noggin is able to block hypertrophy in our cell 
culture system. 
4.2.3.1 Histological analysis 
Under standard chondrogenic conditions histological analysis did not identify any 
effect of noggin on the phenotype of day 28 pellets. DMMB staining showed that 
noggin treated MSC pellets differentiated chondrogenically and showed hyaline 
cartilage like morphology (Figure 22 B, C) similar to chondrogenic control 
aggregates (Figure 22 A). Both, in chondrogenic control aggregates (Figure 22 D) 
and noggin treated chondrogenic aggregates (Figure 22 E, F) some ALP positive 
cells were detected throughout the aggregates, without differences between the 
conditions. No difference in collagen type II staining can be detected between 
chondrogenic control aggregates (Figure 22 G) and noggin treated aggregates 
(Figure 22 H, I). Collagen type X staining was weak both in chondrogenic control 
aggregates (Figure 22 J) and noggin treated aggregates (Figure 22 K, L) without 
differences between these conditions.  
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Figure 22 Histological appearance of MSC pellet cultures on day 28 after noggin treatment 
under chondrogenic conditions. No change in DMMB (A, B, C), ALP (D, E, F), collagen type II (G, 
H, I) and collagen type X (J, K, L) staining can be detected between chondrogenic control conditions 
(A, D, G) and noggin treated conditions (B, C, D, F, H, I). Scale bar = 200 µm. 
 
 
Under pro-hypertrophic conditions noggin treatment inhibited hypertrophy induction 
in a dose dependant manner. DMMB staining showed the distinct hypertrophic 
phenotype with increased cell size in hypertrophic control conditions (Figure 23 A). 
10 ng/ml noggin clearly reduced the amount and size of hypertrophic cells (Figure 
23 B) and at 100 ng/ml noggin no hypertrophic cells could be detected (Figure 23 
C). The amount of ALP positive cells was decreased in noggin treated aggregates in 
the centre of the aggregates (Figure 23 E, F) compared to hypertrophic control 
aggregates (Figure 23 D). Cells in the periphery were ALP positive in both, control 
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and noggin treated hypertrophic conditions. Collagen type X immunostaining was 
strong in hypertrophic control aggregates (Figure 23 J) and decreased with 
increasing noggin concentration (Figure 23 K, L). Of note, high doses of noggin lead 
to a dedifferentiation of the cells shown by decreased metachromatic DMMB 
staining (Figure 23 C) and decreased collagen type II staining (Figure 23 H, I).  
 
 
 
Figure 23 Histological appearance of MSC pellet cultures on day 28 after noggin treatment 
under hypertrophy enhancing conditions. Noggin treatment inhibits hypertrophy shown by 
decreased amount of hypertrophic (A, B, C) and ALP positive cells (D, E, F) and decreased collagen 
type X staining (J, K, L) in noggin treated aggregates (B, C, E, F, K, L) compared to hypertrophic 
control aggregates (A, D, J) . Collagen type II is decreased in noggin treated pellets (H, I) compared 
to hypertrophic control pellets (G). Scale bar = 200 µm.  
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4.2.3.2 Histomorphometry 
Histological analysis indicated that the cell size of MSC pellets decreased after 
noggin treatment under hypertrophic conditions. In order to confirm this, we 
performed a histomorphometric cell size analysis of day 28 aggregates. 
Under chondrogenic conditions, noggin treatment had no effect on the cell size. 
There is no difference in the cell size between chondrogenic control aggregates and 
noggin treated aggregates. Under hypertrophic conditions, noggin treatment 
significantly decreased the cell size (Figure 24). 
 
 
 
Figure 24 Histomorphometric cell size analysis of MSC pellets on day 28 after noggin 
treatment. Under chondrogenic conditions (chon) noggin treatment has no influence on the cell size. 
Under hypertrophic conditions (hyp) noggin treatment significantly reduces the cell size. n = 4 
different donors. 
 
 
4.2.3.3 ALP activity in the medium supernatant 
Additionally, ALP activity in the medium supernatant was investigated on day 28 
after noggin treatment. Noggin treatment did not significantly change ALP activity 
under chondrogenic conditions. Under hypertrophic conditions, ALP activity was 
reduced dose-dependently and significantly by noggin treatment. In addition, ALP 
activity is significantly increased under hypertrophic control conditions compared to 
chondrogenic control conditions (Figure 25). 
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Figure 25 ALP activity in the medium of day 28 MSC pellets after noggin treatment. Under 
chondrogenic conditions (chon) noggin treatment has no influence on ALP activity. Under 
hypertrophic conditions (hyp) noggin treatment significantly reduces ALP activity. ALP activity under 
hypertrophic standard conditions is significantly increased compared to chondrogenic standard 
conditions. n=4 different donors.  
 
 
4.2.3.4 Gene expression analysis 
To further investigate the effect of noggin we performed gene expression analysis of 
collagen type II, collagen type X and BMP4 after noggin treatment.  
Under chondrogenic conditions, noggin treatment did not have a significant effect on 
collagen type II or X expression (Figure 26 A, B). Under hypertrophic conditions 
collagen type II expression is significantly reduced by noggin treatment on day 28 
(Figure 26 A) and collagen type X expression is significantly decreased on day 21 
and day 28 in noggin treated pellets compared to hypertrophic control pellets 
(Figure 26 B). The ratio collagen type II / collagen type I can be taken as a 
chondrogenic differentiation index (Martin, I. et al., 2001). Here we use the ratio 
collagen type X / collagen type II as a hypertrophic differentiation index. The ratio 
collagen type X / collagen type II on day 28 under hypertrophic control conditions is 
1,8. Noggin treatment decreases this ratio. Treatment with 10 ng/ml noggin slightly 
decreases the ratio to 1,5 and after treatment with 100 ng/ml noggin the ratio is 
reduced to 0,95. This indicates that noggin has a stronger inhibitory effect on the 
hypertrophic differentiation than chondrogenic differentiation.  
BMP4 gene expression was not influenced by noggin under chondrogenic 
conditions whereas under hypertrophic conditions 100 ng/ml noggin significantly 
increased BMP4 expression on day 21 and day 28 (Figure 26 C). 
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Figure 26 Gene expression analysis of collagen type II, collagen type X and BMP4 normalized 
to HPRT in MSC pellet cultures after noggin treatment under chondrogenic (chon) and 
hypertrophy enhancing (hyp) conditions analyzed by real time PCR. Collagen type II and 
collagen type X expression is significantly down-regulated after noggin treatment under hypertrophic 
conditions but not under chondrogenic conditions (A, B). Noggin treatment in high doses (100 ng/ml) 
significantly increases BMP4 expression under hypertrophic but not under chondrogenic conditions 
(C). n = 4 different donors.  
 
 
4.2.4 BMP signalling activity 
The principal effectors downstream of BMP receptors are the Smad transcription 
factors, Smad1, 5 and 8. Upon activation of the BMP signalling pathway, Smad1, 5, 
8 get phosphorylated. In order to investigate Smad activation we performed Western 
Blot analysis using antibodies specific for the phosphorylated form of Smad1, 5. 
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Previous results pointed towards an increased BMP signalling activity under 
hypertrophic conditions. In the Western Blot analysis we did not detect a clear 
difference in the amount of phospho-Smad1, 5 between chondrogenic and 
hypertrophic MSC pellets on day 21 and day 28. On day 28 a tendency towards 
decreased phospho-Smad 1, 5 was visible. The total amount of Smad1 protein and 
ß actin was taken as loading control (Figure 27 A). 
Activated Smad complexes accumulate in the nucleus. Therefore we performed 
immunohistochemistry for phospho-Smad1, 5, 8 in order to investigate whether we 
can detect differences in the localisation of phospho-Smad 1, 5, 8 between 
chondrogenic and hypertrophic conditions. In chondrogenic pellets we detected a 
diffuse staining of the cytoplasm of the cells (Figure 27 B) whereas under 
hypertrophic conditions we saw a strong staining of the nucleus indicating an 
accumulation of phospho-Smad1, 5, 8 in the nucleus of hypertrophic cells (Figure 27 
C).  
 
 
 
Figure 27 BMP signalling activity. A Western Blot analysis of Smad 1, 5 protein. No clear 
difference in the amount of phospho-Smad1, 5 can be detected between chondrogenic and 
hypertrophic conditions. The total amount of Smad1 and ß actin was taken as loading control. B, C 
Immunohistochemistry for phospho-Smad1, 5, 8. Increased accumulation of phospho-Smad1, 5, 8 in 
the nucleus under hypertrophic conditions (C) compared to chondrogenic conditions (B).  
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4.2.5 The BMP inhibitor dorsomorphin inhibits thyroid hormone 
induced hypertrophy 
We clearly showed that BMP signalling associated genes are up-regulated under 
hypertrophic conditions and that under hypertrophic conditions, BMP4 further 
increases hypertrophy whereas hypertrophy is blocked by the BMP inhibitor noggin. 
This strongly suggests an involvement of BMP signalling in the regulation of MSC 
hypertrophy and increased BMP signalling under hypertrophic conditions. We did 
not detect a clear difference in phospho-Smad1,5 between chondrogenic and 
hypertrophic conditions in the Western Blot analysis. It is possible that BMP4 does 
not act via the Smad signalling cascade but activates a non-Smad signalling 
pathway to induce hypertrophy in chondrogenic differentiating MSCs. It has been 
shown that BMPs are able to activate various members of different MAPK pathways 
such as p38 and ERK1/2 and the AKT/PKB pathway independent of Smad proteins 
(Shim, J. H. et al., 2009). 
In order to test this we investigated the effect of the BMP inhibitor dorsomorphin in 
the in vitro hypertrophy model. Dorsomorphin, in contrast to noggin, does not block 
soluble BMPs but blocks BMP induced Smad1, 5, 8 phosphorylation. If BMP4 acts 
via the Smad signalling cascade, dorsomorphin should have a similar effect as 
noggin.  
Histological analysis of day 28 pellets showed that under chondrogenic conditions 
there is no difference in the phenotype of dorsomorphin treated pellets and 
chondrogenic control pellets. Dorsomorphin treated pellets differentiated 
chondrogenically characterized by a hyaline cartilage like morphology with little sign 
of hypertrophy (Figure 28 B, C, D) similar to chondrogenic control pellets (Figure 28 
A). ALP staining revealed that both under chondrogenic control conditions (Figure 
28 E) and dorsomorphin treated conditions (Figure 28 F, G, H) some ALP positive 
cells are present. In addition there is no difference in collagen type II staining 
between chondrogenic control pellets (Figure 28 I) and pellets that were treated with 
dorsomorphin (Figure 28 J, K, L). Collagen type X staining is weak in chondrogenic 
control pellets (Figure 28 M) and in dorsomorphin treated pellets (Figure 28 N, O, 
P). But no differences can be detected between the conditions.  
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Figure 28 Histological appearance of MSC pellet cultures on day 28 after dorsomorphin 
treatment under chondrogenic conditions. No change in DMMB (A-D), ALP (E-H), collagen type II 
(I-L) and collagen type X (M-P) staining can be detected between chondrogenic control conditions 
(A, E, I, M) and dorsomorphin treated conditions (B, C, D, F, G, H, J, K, L, N, O, P). Scale bar = 200 
µm.  
 
 
Under hypertrophic conditions, dorsomorphin inhibits thyroid hormone induced 
hypertrophy similar to noggin. DMMB staining revealed that under hypertrophic 
control conditions the hypertrophic phenotype with plenty of hypertrophic cells 
appears (Figure 29 A). Dorsomorphin treatment inhibits hypertrophy in a dose 
dependent manner (Figure 29 B, C, D). 0,5 µM dorsomorphin clearly reduced the 
amount of hypertrophic cells (Figure 29 B). In MSC pellets that were treated with 3 
µM dorsomorphin only few hypertrophic cells can be detected (Figure 29 C) and 
application 10 µM dorsomorphin blocked the appearance of hypertrophic cells and 
cells dedifferentiated (Figure 29 D). In hypertrophic control pellets lots of ALP 
positive cells can be detected (Figure 29 E). The number of ALP positive cells is 
dose dependently reduced after dorsomorphin treatment (Figure 29 F, G, H). 
Collagen type II staining is strong in hypertrophic control aggregates (Figure 29 I). 
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Treatment with 0,5 µM dorsomorphin does not alter collagen type II staining (Figure 
29 J) but addition of 3 µM and 10 µM dorsomorphin clearly reduced collagen type II 
staining (Figure 29 K, L). Hypertrophic control pellets showed a strong collagen type 
X staining (Figure 29 M). Collagen type X staining decreases with increasing 
dorsomorphin concentration (Figure 29 N, O, P). In pellets that were treated with 10 
µM dorsomorphin no collagen type X staining can be detected (Figure 29 P).  
 
 
 
Figure 29 Histological appearance of MSC pellet cultures on day 28 after dorsomorphin 
treatment under hypertrophic conditions. Dorsomorphin inhibits hypertrophy shown by a 
decreased amount of hypertrophic (A-D) and ALP positive (E-H) cells and decreased collagen type X 
staining (M-P). Furthermore dorsomorphin reduces collagen type II staining (I-L). Scale bar = 200 
µm. 
 
 
The data obtained here clearly show that dorsomorphin, similar to noggin, blocks 
thyroid hormone induced hypertrophy. This confirms the assumption that BMP 
signalling is important for the establishment of hypertrophy in chondrogenic 
differentiating MSC and that BMP signalling acts, at least in part, via a Smad 1, 5, 8 
dependent pathway.  
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In the previous experiments MSC pellets were treated with dorsomorphin from day 
14 until day 28. In the following we wanted to investigate the effect of dorsomorphin 
treatment from day 1 until day 14. This was done in order to investigate the effect of 
an early inhibition of BMP signalling on the establishment of hypertrophy as real 
time PCR detected a strong up-regulation of BMP2 on day 3. Furthermore another 
part of the MSC pellets was treated with dorsomorphin over the whole culture 
period, from day 1 until day 28. 
Histological analysis of day 28 MSC pellets revealed that under chondrogenic 
conditions treatment with dorsomorphin from day 1 until day 14 has no 
morphological effect. Dorsomorphin treated MSC pellets differentiated 
chondrogenically (Figure 30 B, C, D) similar to chondrogenic control pellets (Figure 
30 A). Only few ALP positive cells appear in chondrogenic control pellets (Figure 30 
E) and dorsomorphin treated pellets (Figure 30 F, G, H). Furthermore no difference 
in collagen type II staining can be detected between chondrogenic control pellets 
(Figure 30 I) and dorsomorphin treated pellets (Figure 30 J, K, L). Collagen type X 
staining is weak in chondrogenic control pellets (Figure 30 M) and in dorsomorphin 
treated pellets (Figure 30 N, O, P). 
Results  
65 
 
 
Figure 30 Histological appearance of MSC pellet cultures on day 28 after dorsomorphin 
treatment from day 1 until day 14 under chondrogenic conditions. No difference in DMMB (A-
D), ALP (E-H), collagen type II (I-L) and collagen type X (M-O) staining can be detected between 
chondrogenic control pellets (A, E, I, M) and dorsomorphin treated pellets (B, C, D, F, G, H, J, K, L, 
N, O, P). Scale bar = 200 µm.   
 
 
Under hypertrophic conditions treatment with the BMP inhibitor dorsomorphin from 
day 1 until day 14 clearly reduced hypertrophy. Treatment with 0,5 µM 
dorsomorphin reduced the amount of hypertrophic cells (Figure 31 B) and treatment 
with 3 µM and 10 µM dorsomorphin totally abolished the appearance of hypertrophic 
cells and the cells dedifferentiated (Figure 31 C, D). ALP staining showed that in 
pellets that were treated with 0,5 µM dorsomorphin less hypertrophic cells 
developed (Figure 31 F) compared to hypertrophic control conditions (Figure 31 E). 
After treatment with high doses of dorsomorphin (3 µM, 10 µM) no ALP positive 
cells can be detected (Figure 31 G, H). There is no distinct difference in collagen 
type II staining between hypertrophic control pellets (Figure 31 I) and pellets that 
were treated with 0,5 µM dorsomorphin (Figure 31 J). However, in pellets that were 
treated with 3 µM and 10 µM dorsomorphin only very weak and no collagen type II 
staining can be detected (Figure 31 K, L). Collagen type X staining is strong in 
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hypertrophic control pellets (Figure 31 M). Some collagen type X staining can be 
detected in MSC pellets that were treated with 0,5 µM dorsomorphin (Figure 31 N). 
No collagen type X staining can be detected in MSC pellets that were treated with 
higher dorsomorphin doses (Figure 31 O, P). Of note, MSC pellets that were treated 
with high doses of dorsomorphin were smaller compared to hypertrophic control 
pellets and dedifferentiated completely.  
 
 
 
Figure 31 Histological appearance of MSC pellet cultures on day 28 after dorsomorphin 
treatment from day 1 until day 14 under hypertrophic conditions. Low doses of dorsomophin 
reduce the amount of hypertrophic (B), ALP positive (F) cells and collagen type X staining (N) 
compared to hypertrophic control conditions (A, E, I, M). High doses of dorsomorphin lead to a 
dedifferentiation of the cells and the pellets size is reduced (C, D, G, H, K, L, O, P). Scale bar = 200 
µm.  
 
 
In a further experiment the impact of dorsomorphin treatment over the whole culture 
period from day 1 until day 28 was investigated. 
Histological analysis of day 28 MSC pellets showed that under chondrogenic 
conditions, dorsomorphin treated pellets differentiated chondrogenically and showed 
a hyaline cartilage like morphology (Figure 32 B, C, D) similar to that of 
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chondrogenic control pellets (Figure 32 A). In chondrogenic control conditions some 
ALP positive cells can be detected (Figure 32 E) but with increasing dorsomorphin 
concentration the amount of ALP positive cells decreases (Figure 32 F, G, H). In 
pellets that were treated with 10 µM dorsomorphin no ALP positive cells can be 
detected (Figure 32 H). Collagen type II staining is unchanged in dorsomorphin 
treated MSC pellets (Figure 32 J, K, L) compared to chondrogenic control pellets 
(Figure 32 I). Collagen type X staining is weak in chondrogenic control pellets 
(Figure 32 M) and MSC pellets that were treated with low doses of dorsomorphin 
(0,5 µM, 3 µM) (Figure 32 N, O). In MSC pellets that were treated with 10 µM 
dorsomorphin over the whole culture period no collagen type X staining can be 
detected (Figure 32 P). 
 
 
 
Figure 32 Histological appearance of MSC pellet cultures on day 28 after dorsomorphin 
treatment from day 1 until day 28 under chondrogenic conditions. No difference in DMMB, ALP, 
collagen type II, collagen type X staining can be detected between chondrogenic control pellets (A, 
E, I, M) and dorsomorphin treated pellets with low doses (B, C, F, G, J, K, N, O). High doses of 
dorsomorphin reduce the amount of ALP positive cells (H) and collagen type X staining (P) without 
affecting collagen type II staining (L). Scale bar = 200 µm.   
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Under hypertrophic conditions treatment with dorsomorphin over the whole culture 
period clearly reduced hypertrophy. In MSC pellets that were treated with 0,5 µM 
dorsomorphin some hypertrophic and ALP positive cells developed (Figure 33 B, F). 
The number of hypertrophic, ALP positive cells is however reduced compared to 
hypertrophic control conditions (Figure 33 A, F). MSC pellets that were treated with 
3 µM and 10 µM dorsomorphin dedifferentiated and no hypertrophic cells and no 
ALP positive cells can be detected (Figure 33 C, D, G, H). There is no difference in 
collagen type II staining between hypertrophic control conditions (Figure 33 I) and 
MSC pellets that were treated with 0,5 µM dorsomorphin (Figure 33 J). However in 
MSC pellets that were treated with higher dorsomorphin concentrations (3 µM, 10 
µM) only very weak collagen type II staining can be detected (Figure 33 K, L). In 
addition, collagen type X staining is clearly reduced after dorsomorphin treatment. 
After application of 0,5 µM dorsomorphin collagen type X staining is weak (Figure 33 
N) and with 3 µM and 10 µM dorsomorphin no collagen type X staining can be 
detected (Figure 33 O, P). Of note, the size of MSC pellets that were treated with 3 
µM and 10 µM dorsomorphin was clearly reduced compared to hypertrophic control 
pellets.  
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Figure 33 Histological appearance of MSC pellet cultures on day 28 after dorsomorphin 
treatment from day 1 until day 28 under hypertrophic conditions. Low doses of dorsomorphin 
reduce the amount of hypertrophic, ALP positive cells and collagen type X staining (B, F, N) 
compared to hypertrophic control conditions (A, E, I, M). High doses of dorsomorphin lead to a 
dedifferentiation of the cells and the pellets size is reduced (C, D, G, H, K, L, O, P). Scale bar = 200 
µm.  
 
Taken together, these results showed that under chondrogenic conditions 
dorsomorphin has no effect on chondrogenic differentiation and hypertrophic extend 
when applied from day 1 until day 14 or from day 14 to day 28. However application 
of dorsomorphin over the whole culture period reduces hypertrophic markers but 
has no influence on chondrogenic markers.  
Under hypertrophic conditions administration of dorsomorphin from day 14 until day 
28 lead to a dose dependent reduction in the amount of hypertrophic cells, ALP 
positive cells and a reduction in collagen type X. High doses of dorsomorphin lead 
to a dedifferentiation of the cells. Administrations of low doses dorsomorphin from 
d1 until day 14 or over the whole culture period reduce the amount of hypertrophic 
cells, whereas higher dorsomorphin concentrations lead to a dedifferentiation of the 
cells.  
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4.2.6 The role of BMP signalling modulators in MSC hypertrophy 
The BMP signalling pathway is regulated and modulated by a network of different 
regulators. Soluble antagonists specifically bind to the growth factors and prevent 
their interaction with their receptors. Co-receptors modulate the transmission of the 
extracellular signal to the cytosol. In the following part we aimed to analyze whether 
there are differences in the expression of different BMP antagonists between 
chondrogenic and hypertrophic conditions. 
4.2.6.1 Soluble BMP antagonists 
The family of BMP antagonists consists of structurally unrelated proteins that differ 
in its specificity and affinity for different BMPs. We investigated the expression of the 
most prominent BMP antagonists, noggin, chordin, follistatin and gremlin, 
comparative between chondrogenic and hypertrophic MSC pellets. Differences in 
the level at which BMP antagonists are expressed may lead to differences in BMP 
signalling activities.  
Real time PCR revealed that noggin is significantly down-regulated in hypertrophic 
MSC pellets on day 17. On culture day 21 there is a tendency towards reduced 
noggin expression in hypertrophic aggregates but on day 28 there is no difference in 
the expression of noggin between chondrogenic and hypertrophic conditions (Figure 
34 A). The BMP antagonist chordin is significantly down-regulated in hypertrophic 
aggregates on day 28 (Figure 34 B). Surprisingly, the BMP antagonist gremlin is 
significantly up-regulated under hypertrophic condition on day 17, day 21 and day 
28 (Figure 34 C). Follistatin is not regulated as a function of hypertrophy. There is 
no difference in the expression of follistatin between chondrogenic and hypertrophic 
MSC pellets on day 17, day 21 and day 28 (Figure 34 D). 
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Figure 34 Gene expression analysis of noggin, chordin, gremlin and follistatin normalized to 
HPRT in MSC pellet cultures under chondrogenic and hypertrophy enhancing conditions 
analyzed by real time PCR. Noggin is significantly down-regulated under hypertrophic conditions on 
day 17 (A) and chordin is down-regulated on day 28 under hypertrophic conditions (B). Gremlin is 
up-regulated under hypertrophic conditions on day 17, 21 and 28 (C). Follistatin is not regulated as a 
function of hypertrophy (D). n= 7 different donors. 
 
 
4.2.6.2 The co-receptor BAMBI 
The pseudoreceptor BAMBI (BMP and activin membrane-bound inhibitor) is known 
as an inhibitor of the TGFß and BMP signalling pathway (Onichtchouk, D. et al., 
1999; Sekiya, T. et al.). BAMBI is a transmembrane protein that has structural 
similarity to type I receptors of the TGFß family but lacks the intracellular kinase 
domain (Onichtchouk, D. et al., 1999; Loveland, K. L. et al., 2003). BAMBI is able to 
bind to type I receptors and thereby inhibits the formation of type I/II receptor 
complexes and consequently inhibits signal transduction (Figure 35 A). 
Real time PCR analysis of BAMBI revealed a pronounced increase in BAMBI 
expression under hypertrophic conditions. BAMBI expression is significantly up-
regulated on culture day 17, day 21 and day 28 in hypertrophic MSC pellets 
compared to chondrogenic pellets (Figure 35 B). 
To confirm this result on protein level we performed immunohistochemistry and 
Western Blot analysis for BAMBI. Immunohistochemistry revealed increased BAMBI 
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staining in hypertrophic aggregates compared to chondrogenic aggregates. 
Hypertrophic cells show a strong BAMBI staining in the cytoplasm and membrane 
whereas BAMBI staining of chondrogenic cells is only weak (Figure 35 C). 
Furthermore Western Blot analysis of BAMBI demonstrated that the amount of 
BAMBI protein is strongly enhanced under hypertrophic conditions. Under 
chondrogenic conditions nearly no BAMBI protein can be detected whereas on day 
21 and especially on day 28 under hypertrophic conditions a strong BAMBI protein 
band can be detected (Figure 35 D). 
 
 
 
Figure 35 BAMBI expression in chondrogenic and hypertrophic MSC pellets. A Model of 
BMP/TGFß signalling inhibiton by Bambi. Bambi prevents the dimerization of type I and type II 
receptors and thereby inhibits signal transduction. B Gene expression analysis of BAMBI normalized 
to HPRT in MSC pellet cultures under chondrogenic and hypertrophy enhancing conditions analyzed 
by real time PCR. Bambi is significantly up-regulated under hypertrophic conditions on day 17, day 
21 and day 28 under hypertrophic conditions. n=7 different donors. C Immunohistochemistry of 
Bambi. Bambi staining is increased under hypertrophic conditions compared to chondrogenic 
conditions. Scale bar=200 µm and 50 µm. D Western Blot analysis of Bambi. Increased amount of 
Bambi protein can be detected under hypertrophic conditions on day 21 and day 28 compared to 
chondrogenic conditions. ß actin was taken as loading control. 
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To further investigate the role of BAMBI in the induction of hypertrophy, we analysed 
the expression of BAMBI after BMP4 and noggin treatment. BMP4 treatment 
significantly increases BAMBI expression on day 28 under chondrogenic conditions. 
Under hypertrophic conditions BAMBI expression is significantly increased in MSC 
pellets that were treated with BMP4 compared to hypertrophic medium without T3 
(Figure 36 A).  
Treatment with the BMP inhibitor noggin does not alter BAMBI expression under 
chondrogenic conditions. Under hypertrophic conditions, noggin treatment 
significantly decreases BAMBI expression on day 21 and day 28 (Figure 36 B).  
These experiments showed that the expression of the pseudoreceptor BAMBI is 
strongly up-regulated under hypertrophy enhancing conditions and BMP4 and 
noggin treatment are able to modulate BAMBI expression. The function of BAMBI is 
not clear and will be investigated by functional experiments with lentiviral knock-
down and over-expression of BAMBI. 
 
 
 
Figure 36 Gene expression analysis of BAMBI normalized to HPRT in MSC pellet cultures after 
BMP4 treatment (A) and noggin treatment (B) under chondrogenic (chon) and hypertrophy 
enhancing (hyp) conditions analyzed by real time PCR. BAMBI expression is increased under 
chondrogenic and hypertrophic conditions after BMP4 treatment (A). Noggin treatment significantly 
decreases BAMBI expression under hypertrophic conditions (B). n=4 different donors.  
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4.3 The role of TGFß signalling in the regulation of hypertrophy in 
chondrogenic differentiating MSCs  
TGFß signalling has been shown to inhibit terminal differentiation of growth plate 
chondrocytes (Ballock, R. T. et al., 1993; Ferguson, C. M. et al., 2000; Ferguson, C. 
M. et al., 2004). The role of TGFß signalling in the suppression of hypertrophy in 
chondrogenic differentiating MSCs is largely unknown. Therefore, in the following 
part, we aimed to clarify if TGFß signalling is involved in the regulation of MSC 
hypertrophy.  
4.3.1  TGFß signalling associated genes are down-regulated under 
hypertrophic conditions 
Comparison of genes associated with TGFß signalling between chondrogenic and 
hypertrophic MSC pellets using real time PCR, revealed that the TGFß receptor 1 
(TGFßR1) is significantly down-regulated under hypertrophic conditions on day 17, 
day 21 and day 28 compared to chondrogenic conditions (Figure 37 A). In addition, 
the TGFß receptor 2 (TGFßR2) is significantly down-regulated on day 28 in 
hypertrophic MSC pellets (Figure 37 B). Sox9 is known to be an important 
transcription factor for chondrocyte differentiation and is a downstream target of 
TGFß signalling. Real time PCR analysis showed that Sox9 is significantly down-
regulated on day 17 and day 21 under hypertrophy enhancing conditions. On day 28 
there is a tendency towards decreased Sox9 expression under hypertrophic 
conditions but not significantly (Figure 37 C). 
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Figure 37 Gene expression analysis of TGFßR1, TGFßR2 and Sox9 normalized to HPRT in 
MSC pellet cultures under chondrogenic and hypertrophy enhancing conditions analyzed by 
real time PCR. TGFßR1 is significantly down-regulated under hypertrophic conditions on day 17, 21 
and 28 (A). TGFßR2 is down-regulated under hypertrophic conditions on day 28 (B). Sox9 is down-
regulated on day 17 and 21 in hypertrophic MSC pellets (C). n= 7 different donors. 
 
 
Analysis of whole cell lysates with Western Blot revealed that, similar to the gene 
expression analysis, the TGFßR1 protein amount is decreased under hypertrophic 
conditions on day 21 and day 28 compared to chondrogenic conditions (Figure 38 
A). Sox9 protein amount is reduced on day 21 in hypertrophic cell pellets but not on 
day 28 (Figure 38 B).  
 
 
 
Figure 38 Western Blot analysis of TGFßR1 and Sox9. TGFßR1 protein amount is reduced on 
day 21 and day 28 under hypertrophic conditions (A). Sox9 protein level is decreased on day 21 
under hypertrophic conditions (B). ß actin was taken as loading control.  
 
Results  
76 
4.3.2 TGFß signalling activity 
Similar to BMP signalling, TGFß signalling utilizes intracellular Smad proteins to 
transduce the signal from the activated receptor to the nucleus. In contrast to BMP 
signalling that activates Smad1, 5, 8, TGFß signalling activates Smad2, 3. In order 
to determine whether there are differences in TGFß signalling activity between 
chondrogenic and hypertrophic MSC pellets Western Blot analysis for the 
phosphorylated forms of Smad2 and Smad3 were performed. 
Western Blot analysis revealed a clear decrease in the amount of phospho-Smad2 
and phospho-Smad3 in hypertrophic MSC pellets compared to chondrogenic 
pellets. During the chondrogenic pre-differentiation phase and on day 21 and day 28 
under chondrogenic conditions a strong phospho-Smad2 and phospho-Smad3 
protein band can be detected. In contrast under hypertrophic conditions nearly no 
phospho-Smad 2 and phospho-Smad3 can be detected on day 21 and day 28. The 
total amount of Smad2 and Smad3 protein and ß actin were taken as loading control 
(Figure 39). This result indicates that TGFß signalling is less active under 
hypertrophic conditions compared to chondrogenic conditions.  
 
 
Figure 39 TGFß signalling activity. Western Blot analysis of phospho-Smad2 and phospho-Smad3 
under chondrogenic and hypertrophic conditions. The amount of phospho-Smad2 and phospho-
Smad3 is reduced under hypertrophic conditions on day 21 and day 28 compared to chondrogenic 
conditions. The total amount of Smad2/Smad3 and ß actin were taken as loading control.   
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4.3.3 The TGFß inhibitor (SB431542) does not increase 
hypertrophy 
The experimental data obtained from above showed that TGFß receptors are down-
regulated under hypertrophic conditions. Furthermore Western Blot analysis of the 
phosphorylated forms of Smad2 and Smad3 revealed a decreased TGFß signalling 
activity under hypertrophic conditions. We hypothesize that the reduced TGFß 
signalling activity under hypertrophic conditions contributes to the enhancement of 
hypertrophy. To confirm this hypothesis, we investigated the effect of the TGFß 
antagonist SB431542 on hypertrophic establishment, in the in vitro hypertrophy 
model. SB431542 inhibits TGFßR1 kinase activity and thereby inhibit the 
phosphorylation of Smad3 (Callahan, J. F. et al., 2002).  
Under chondrogenic conditions treatment with SB431542 from day 14 until day 28 
does not increase hypertrophy. DMMB staining revealed no histological difference 
between MSC pellets that were treated with low doses of SB431542 (Figure 40 B, 
C) and chondrogenic control aggregates (Figure 40 A). In all conditions a hyaline 
cartilage like morphology developed with little sign of hypertrophy. High doses of 
SB431542 lead to a dedifferentiation of the pellets (Figure 40 D). Similarly, there is 
no difference in ALP staining between chondrogenic control aggregates (Figure 40 
E) and SB431542 treated aggregates (Figure 40 F, G, H). In addition, no difference 
in Collagen type II staining can be detected between chondrogenic control pellets 
(Figure 40 I) and MSC pellets that were treated with low doses of SB431542 (Figure 
40 J, K). However, Collagen type II staining is strongly reduced after treatment with 
10 µM SB431542 (Figure 40 L). Collagen type X staining is weak in chondrogenic 
control aggregates (Figure 40 M) and in aggregates treated with low doses of 
SB431542 (Figure 40 N, O). In MSC pellets that were treated with 10 µM SB431542 
no collagen type X staining can be detected (Figure 40 P). 
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Figure 40 Histological appearance of MSC pellet cultures on day 28 after SB431542 treatment 
under chondrogenic conditions. No change in DMMB, ALP, collagen type II and collagen type X 
staining can be detected between chondrogenic control pellets (A, E, I, M) and pellets treated with 
low doses of SB431542 (B, C, F, G, J, K, N, O). High doses of SB431542 lead to a dedifferentiation 
of the cells shown by decreased DMMB staining (D) and collagen type II staining (L). Scale bar = 200 
µm. 
 
 
The previous results showed that inhibition of TGFß signalling with SB431542 does 
not enhance hypertrophy under chondrogenic conditions. Furthermore we 
demonstrated that BMP4 increases hypertrophy under hypertrophic conditions but 
not under chondrogenic conditions. Next we wanted to investigate whether we can 
increase hypertrophy under chondrogenic conditions by inhibiting TGFß signalling 
with SB431542 and simultaneous addition of BMP4. SB431542 and BMP4 were 
added to the medium from day 14 until day 28.  
As already seen in 4.2.2.1, addition of BMP4 to chondrogenic medium has no 
apparent effect on the amount of hypertrophic cells (Figure 41 A). Upon addition of 
the TGFß inhibitor SB431542 the amount of hypertrophic cells increases with 
increasing SB431542 concentration (Figure 41 B, C, D). Furthermore, there are only 
few ALP positive cells in MSC pellets that were only treated with BMP4 (Figure 41 
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E). The amount of ALP positive cells increases in MSC pellets that were treated with 
BMP4 and the TGFß inhibitor (Figure 41 F, G, H) with the highest amount of ALP 
positive cells in pellets that were treated with 10 µM SB431542 (Figure 41 H). 
Collagen type II staining is strong in chondrogenic MSC pellets that were treated 
with BMP4 (Figure 41 I) and collagen type II staining is unchanged in MSC pellets 
that were incubated in chondrogenic medium containing BMP4 and the TGFß 
inhibitor (Figure 41 J, K, L). Of note, MSC pellets that were treated with the highest 
concentration of the TGFß inhibitor SB431542 together with BMP4 do not 
dedifferentiate and show a strong collagen type II staining, indicating that BMP4 
preserves chondrogenic differentiation after SB431542 treatment (Figure 41 L). 
Collagen type X staining is low in chondrogenic MSC pellets that were treated with 
BMP4 (Figure 41 M). Addition of SB431542 together with BMP4 increases Collagen 
type X staining (Figure 41 N, O, P). 
 
 
Figure 41 Histological appearance of MSC pellet cultures on day 28 after SB431542 and BMP4 
treatment under chondrogenic conditions. Concomitant application of SB431542 and BMP4 
increases hypertrophy in a dose dependent manner shown by and increased amount of hypertrophic 
(B-D) and ALP positive (F-H) cells and increased collagen type X staining (N-P) after SB431542 and 
BMP4 treatment, compared to pure BMP4 treatment (A, E, M). No difference in collagen type II 
staining can be detected between BMP4 treated control pellets (I) and pellets treated with SB431542 
and BMP4 (J-L). Scale bar = 200 µm. 
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Under hypertrophic conditions, the TGFß inhibitor SB431542 does not additionally 
enhance hypertrophy. DMMB staining revealed that MSC pellets that were treated 
with SB431542 from day 14 until day 28 show a similar histological phenotype as 
hypertrophic control pellets. No difference in the amount of hypertrophic cells can be 
detected between hypertrophic control pellets (Figure 42 A) and pellets that were 
treated with the TGFß inhibitor (Figure 42 B, C, D). In contrast to chondrogenic 
conditions, high doses of SB431542 do not lead to a dedifferentiation of the cells 
(Figure 42 D). Furthermore there is no difference in the amount of ALP positive cells 
between hypertrophic control aggregates (Figure 42 E) and SB431542 treated 
aggregates (Figure 42 F, G, H). No difference in collagen type II staining can be 
detected between hypertrophic control pellets (Figure 42 I) and pellets that were 
treated with SB431542 (Figure 42 J, K, L). Of note, MSC pellets that were treated 
with 10 µM SB431542 show a strong collagen type II staining (Figure 42 L). 
Collagen type X staining is strong under hypertrophic control conditions (Figure 42 
M). Treatment with 0,5 µM and 3 µM SB431542 does not alter collagen X staining 
(Figure 42 N, O). However, MSC pellets that were treated with 10 µM of SB431542 
show a slightly reduced collagen type X staining (Figure 42 P).  
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Figure 42 Histological appearance of MSC pellet cultures on day 28 after SB431542 treatment 
under hypertrophic conditions. No difference in DMMB, ALP, collagen type II and collagen type X 
staining can be detected between hypertrophic control pellets (A, E, I, M) and SB431542 treated 
pellets (B-D, F-H, J-L, N-P). Scale bar = 200 µm. 
 
 
In summary these results showed that the TGFß inhibitor SB431542 increases 
hypertrophy under chondrogenic conditions when applied together with BMP4. 
Under hypertrophic conditions, the TGFß inhibitor does not further enhance 
hypertrophy.  
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4.4 Involvement of other signalling pathways in the regulation of 
hypertrophy 
This study clearly showed an involvement of BMP and TGFß signalling in the 
regulation of MSC hypertrophy. Biological processes are regulated by different 
signalling pathways that work together to generate a specific outcome.  
In the following we aimed to analyze the influence of other signalling pathways in 
the regulation of MSC hypertrophy. This was done in a preliminary experiment with 
whole genome microarray analysis using samples of one donor. In the evaluations 
we focused on the differential analysis of the expression of genes involved in 
signalling pathways that regulate chondrocyte differentiation, FGF, Indian 
hedgehog/PTHrP and Wnt signalling.  
4.4.1 FGF signalling 
Gene expression analysis showed that many FGF signalling associated genes are 
regulated in the in vitro hypertrophy model indicating a role of this signalling 
pathway in the regulation of MSC hypertrophy. For instance, FGF receptors 
(FGFR1, FGFR2 and FGFR3) and FGF14 and FGF7 are up-regulated under 
hypertrophic conditions. FGF1 is down-regulated under hypertrophic conditions 
(Table 5).  
 
FGF signalling pathway 
Gene d17 d21 d28 Gene function 
BGLAP 
 
- +3,1 
 
+3,9 
 
Bone gamma-carboxyglutamate protein 
CDH2 
 
- +2,8 
 
+4,4 
 
Cadherin 2 
FGF1 
 
-2,6 
 
-3,3 
 
-8,0 
 
fibroblast growth factor 1 
FGF14 
 
- +2,5 
 
+3,9 
 
fibroblast growth factor 14 
FGF7 
 
- - +2,4 
 
fibroblast growth factor 7 
FGFR1 
 
- +2,3 
 
+2,4 
 
fibroblast growth factor receptor 1 
FGFR2 +2,4 +4,1 +5,8 fibroblast growth factor receptor 2 
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FGFR3 
 
- - +2,2 
 
fibroblast growth factor receptor 3 
FOS -3,0 
 
-3,6 -5,4 
 
FBJ murine osteosarcoma viral oncogene homologe 
transcription factor 
GAB1 
 
- +2,2 
 
+3,4 
 
GRB2-associated binding protein 1 
HGF 
 
+4,8 
 
+2,9 
 
+4,0 
 
hepatocyte growth factor 
SPP1 - -2,4 
 
-2,2 
 
Secreted phosphoprotein 1 
 
+ fold up-regulation under hypertrophic conditions, - fold down-regulation under hypertrophic 
conditions 
Table 5 Regulation of FGF signalling associated genes in the in vitro hypertrophy model. 
 
 
4.4.2 Indian hedgehog signalling 
Hedgehog signalling associated genes are regulated as a function of hypertrophy. 
Indian hedgehog (IHH) and the IHH receptor Patched 1 (PTCH1) are up-regulated 
under hypertrophic conditions. Modulators of Indian hedgehog signalling like 
dispatched homolog 1 (DISP1) and hedgehog interacting protein (HHIP) are also 
up-regulated in hypertrophic MSC pellets (Table 6).   
 
Indian Hedgehog Signalling 
 
Gene d17 d21 d28 Gene function 
 
DISP1 
 
- +2,4 
 
+3,4 
 
 
Dispatched homolog 1, required for hedgehog signalling 
 
HHIP 
 
- +2,0 
 
+3,0 
 
 
Hedgehog interacting protein 
 
IHH 
 
- +2,2 
 
+3,0 
 
Indian hedgehog 
PTCH1 
 
- - +2,3  Patched 1, receptor for sonic hedgehog 
 
+ fold up-regulation under hypertrophic conditions, - fold down-regulation under hypertrophic 
conditions 
Table 6 Regulation of hedgehog signalling associated genes in the in vitro hypertrophy model. 
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4.4.3 Wnt signalling 
Microarray analysis detected differences in the expression of Wnt signalling 
associated genes between chondrogenic and hypertrophic conditions. The Wnt 
receptor FZD5 (Frizzled homolog 5) and the co-receptor LRP5 (Low density 
lipoprotein receptor-related protein 5) are up-regulated under hypertrophic 
conditions. Furthermore the Wnt signalling inhibitor DKK1 (dickkopf homolog 1) is 
strongly down-regulated under hypertrophic conditions (Table 7).  
 
 
Wnt Signalling 
 
Gene d17 d21 d28 Gene function 
ANKRD6 -3,4 
 
-3,7 -3,4 
 
 
Ankyrin repeat domain 6 
DAB2 
 
+2,2 
 
+2,4 
 
 
+2,1 
 
 
Disabled homolog 2, mitogen-responsive phophoprotein 
DKK1 
 
 
-14,7 
 
-5,9 
 
 
- Dickkopf homolog 1, inhibitor of Wnt signalling 
FZD5 
 
 
- +2,2 
 
+2,2 
 
Frizzled homolog 5, receptor for Wnt signalling 
LRP5 
 
- - +2,1 
 
Low density lipoprotein receptor-related protein 5, co 
receptor for Frizzled 
 
+ fold up-regulation under hypertrophic conditions, - fold down-regulation under hypertrophic 
conditions 
Table 7 Regulation of Wnt signalling associated genes in the in vitro hypertrophy model. 
 
 
 
These data point towards increased canonical Wnt signalling under hypertrophic 
conditions. In the absence of canonical Wnt signalling cytosolic ß-catenin is 
phosphorylated by the GSK-3ß and becomes ubiquitynated and directed for 
proteasom-assisted degradation. Upon activation of the Wnt signalling pathway, the 
GSK-3ß is inhibited resulting in decreased ß-catenin phosphorylation and 
degradation. Western Blot analysis of phospho-ß-catenin showed decreased 
phosphorylation of ß-catenin under hypertrophic conditions, indicating increased 
Wnt signalling activity in hypertrophic MSC pellets (Figure.43).  
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Figure 43 Western Blot analysis of phospho-ß-catenin. The amount of phospho-ß-catenin is 
reduced under hypertrophic conditions on day 21 and 28 compared to chondrogenic conditions. ß 
actin was taken as loading control.  
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5 Discussion 
5.1 Induction of hypertrophy 
Human MSCs are able to differentiate chondrogenically, however some 
hypertrophic markers are expressed. This hypertrophic phenotype of chondrogenic 
differentiating MSCs can be experimentally enhanced by changing medium 
conditions from chondrogenic to hypertrophy enhancing medium as described 
previously (Mueller, M. B. & Tuan, R. S., 2008; Mueller, M. B. et al., 2010). This 
change in medium conditions includes withdrawal of TGFß and dexamethasone and 
the addition of the thyroid hormone T3. Using this in vitro hypertrophy model for 
MSCs we could significantly increase the hypertrophic phenotype of chondrogenic 
differentiating MSCs. The enhancement of hypertrophy was clearly shown by an 
increased cell size, stronger collagen type X staining, higher ALP activity and 
increased expression osteocalcin in hypertrophic MSC pellets. Hypertrophy markers 
are not exclusively expressed under pro-hypertrophic conditions but also under 
standard chondrogenic conditions but to a lower degree. There are some ALP 
positive cells in the centre of chondrogenic MSC pellets but ALP activity is mainly 
restricted to the periphery of the pellet. It was described recently that fibroblast like 
cells surround MSC pellets (Yoo, J. U. et al., 1998). Based on this, we suppose that 
the ALP positive ring consists of fibroblast like cells rather than hypertrophic cells. 
On protein level we detected a clear difference in collagen type X between 
chondrogenic and hypertrophic MSC pellets but on gene expression level no 
significant differences between hypertrophic and chondrogenic conditions can be 
detected. This phenomenon has been described by other investigators (Barry, F. et 
al., 2001; Sekiya, I. et al., 2002; Mwale, F. et al., 2006). The reason therefore is 
unclear. Post-transcriptional modulations may account for that phenomenon. In 
addition, after hypertrophic induction, areas of cellular hypertrophy as well as 
dedifferentiated areas were detected. The dedifferentiated areas may attenuate the 
collagen type X signal in the PCR under hypertrophic conditions.  
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5.2 Influence of BMP signalling on MSC hypertrophy 
A huge amount of studies demonstrated that BMPs play a significant role during the 
process of endochondral ossification in skeletal development (Yoon, B. S. & Lyons, 
K. M., 2004). It has been shown that BMPs promote mesenchymal condensation, 
chondrogenic differentiation and maturation towards the hypertrophic chondrocyte. 
In order to examine whether the BMP signalling pathway may also be involved in 
the regulation of MSC hypertrophy we performed a differential gene expression 
analysis of components of BMP signalling including ligands, receptors and 
transcription factors, comparative between chondrogenic and hypertrophic MSC 
aggregates. We detected a clear up-regulation of BMP4 under hypertrophy 
enhancing conditions whereas BMP2 was not regulated and BMP7 mRNA could not 
be detected in an amount sufficient for proper quantification. Among BMP ligands 
we focused on these three growth factors as they are expressed by growth plate 
chondrocytes undergoing endochondral ossification (Wozney, J. M. & Rosen, V., 
1998) and are all able to induce hypertrophy of cultured embryonic chondrocytes 
(Suzuki, F., 1992; Rosen, V. et al., 1994; Leboy, P. S. et al., 1997; Volk, S. W. et al., 
1998). BMP4 was also regulated on protein level and, in contrast to BMP2 and 
BMP7, BMP4 seems to play a role in the enhancement of hypertrophic 
differentiation in chondrogenic differentiating MSCs in the in vitro hypertrophy 
model. Consistent with these findings are studies on embryonic chondrocytes that 
showed that BMP2, 4 and 7 are all capable of inducing hypertrophy in chick 
embryonic chondrocytes but BMP4 is more effective than other BMPs (Volk, S. W. 
et al., 1998). Furthermore in vivo studies showed that overexpression of BMP4 in 
the cartilage of transgenic mice resulted in an increased hypertrophic zone 
indicating increased differentiation into hypertrophic chondrocytes (Tsumaki, N. et 
al., 2002). In mouse growth plate chondrocytes, thyroid hormone enhances 
hypertrophy by induction of BMP2 (Ballock, R. T. & O'Keefe, R. J., 2003). In addition 
a recent study showed that the thyroid hormone T3 stimulates collagen type X 
expression in cultured chick chondrocytes through stimulation of BMP4 expression 
(Lassova, L. et al., 2009). These studies indicate that thyroid hormone effects on 
chondrocyte maturation are mediated, at least in part, by stimulation of BMP 
signalling. Similar to this these results indicate that in human MSCs thyroid hormone 
induces hypertrophy through induction of BMP4.  
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Analysis of BMP receptor expression revealed that the BMPR1B is significantly up-
regulated in hypertrophic aggregates. In contrast, other BMP receptors (BMPR1A, 
Alk2, BMPR2) were not regulated upon induction of hypertrophy in our experiments. 
Studies with constitutive active (CA) and dominant negative (DN) BMP receptors 
showed that CA BMPR1B increased ALP activity and collagen type X expression in 
embryonic chick sternum chondrocytes. The effect of BMPR1A was less 
pronounced. DN BMPR1B in sternum chondrocytes blocked BMP induced 
hypertrophy more efficiently than DN BMPR1A. This indicates that the major type I 
BMP receptor involved in chondrocyte hypertrophy is BMPR1B (Enomoto-Iwamoto, 
M. et al., 1998; Volk, S. W. et al., 2000; Grimsrud, C. D. et al., 2001). This 
assumption is consistent with our observation of increased BMPR1B expression in 
hypertrophic MSC aggregates. Our results suggest that BMPR1B could be the main 
receptor for transduction of pro-hypertrophic BMP signals in chondrifying MSCs. 
However, this needs to be confirmed by functional experiments. 
Prior studies showed that BMP2, 4 and 7 induce the expression of the transcription 
factor Runx2 (Tsuji, K. et al., 1998; Lee, K. S. et al.; Nishimura, R. et al., 2002). 
Runx2 is expressed in chondrocytes at low level at the beginning of cartilage 
development and is strongly up-regulated in hypertrophic chondrocytes (Inada, M. et 
al., 1999; Kim, I. S. et al., 1999). Runx2 seems to be an essential transcription factor 
for chondrocyte terminal differentiation (Enomoto, H. et al., 2000; Enomoto-
Iwamoto, M. et al., 2001; Takeda, S. et al., 2001; Ueta, C. et al., 2001). In Runx2 
deficient mice chondrocyte maturation is decreased (Inada, M. et al., 1999; Ueta, C. 
et al., 2001) and over-expression of Runx2 in growth plate chondrocytes leads to 
increased chondrocyte hypertrophy (Takeda, S. et al., 2001; Ueta, C. et al., 2001). 
Based on these data we hypothesized that increased BMP4 expression in 
hypertrophic MSC pellets activates Runx2 expression and Runx2 in turn activates 
the expression of genes involved in the establishment of hypertrophy. It has been 
shown that different hypertrophy associated markers like osteocalcin (Geoffroy, V. 
et al., 2002), collagen type X (Leboy, P. et al., 2001), matrix metalloproteinase 
(MMP)-13 (Jimenez, M. J. et al., 1999) and VEGF (Zelzer, E. et al., 2001) are 
activated by Runx2. We were able to demonstrate that Runx2 is significantly up-
regulated in hypertrophic aggregates compared to chondrogenic aggregates. Similar 
to embryonic development, during chondrocyte pre-differentiation Runx2 is 
expressed to a low degree and the expression strongly increases under 
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hypertrophic conditions with the highest Runx2 expression on day 28. This suggests 
that Runx2 is an essential transcription factor for the terminal differentiation of 
MSCs. However, the observed increase in Runx2 expression seems not to be 
controlled exclusively by BMP signalling as real time PCR analysis revealed that 
treatment of MSCs with BMP4 does not significantly increase Runx2 expression and 
inhibition of BMP signalling with the BMP inhibitor noggin does not significantly 
decrease Runx2 expression (data not shown). This indicates that Runx2 expression 
may be regulated by different signalling pathways. Other signalling molecules have 
been shown to regulate Runx2 expression, among them retinoids (Jimenez, M. J. et 
al., 1999), PTHrP (Guo, J. et al., 2006) and FGF (Zhou, Y. X. et al., 2000). Wnt 
signalling has also been shown to induce Runx2 expression (Gaur, T. et al., 2005). 
Microarray data showed a pronounced down-regulation of the Wnt inhibitor DKK1 
under hypertrophic conditions and Western Blot analysis for phospho-ß-catenin 
demonstrated decreased amount of phospho-ß-catenin in hypertrophic MSC pellets. 
This points towards increased canonical Wnt signalling under hypertrophic 
conditions and may contribute to increased Runx2 expression in hypertrophic MSC 
pellets. In addition TGFß and dexamethasone decrease Runx2 expression (Alliston, 
T. et al., 2001; Kang, J. S. et al., 2005; Li, X. et al., 2005). Under hypertrophic 
conditions in the in vitro hypertrophy model, TGFß and dexamethasone are 
excluded from the medium and this may lead to a reduced suppression of Runx2 
expression through TGFß and dexamethasone and therefore increased Runx2 
expression.  
Previous results demonstrated that BMP4 is strongly up-regulated under 
hypertrophic conditions and points towards a significant role of BMP4 in the 
induction of hypertrophy. In order to investigate a functional role of this up-regulation 
we investigated the effect of recombinant human BMP4 on chondrogenic 
differentiating MSCs. Hypertrophy in the in vitro hypertrophy model of chondrogenic 
differentiating MSCs is induced by withdrawal of TGFß and dexamethasone and the 
addition of thyroid hormone (Mackay, A. M. et al., 1998; Mueller, M. B. & Tuan, R. 
S., 2008). Different studies showed that thyroid hormone is able to induce 
hypertrophy in embryonic mesenchymal cells, growth plate chondrocytes and MSCs 
(Leboy, P. S. et al., 1997; Mackay, A. M. et al., 1998; Okubo, Y. & Reddi, A. H., 
2003; Mueller, M. B. & Tuan, R. S., 2008). Here we demonstrated that in 
hypertrophic medium after withdrawal of TGFß and dexamethasone but without 
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addition of T3, both the cell size and ALP activity remained relatively low, but are 
increased compared to standard chondrogenic medium. Addition of T3 to this 
medium, which results in our standard pro-hypertrophic medium, clearly enhanced 
hypertrophy shown by an increased cell size, an increased amount of hypertrophic 
cells and increased ALP activity. The addition of BMP4 instead of T3 to the medium 
significantly increased cell size, ALP activity and collagen type X expression 
compared to hypertrophic medium with and without T3. BMP4 has a very strong 
pro-hypertrophic effect and seems to be more effective in inducing hypertrophy of 
chondrogenic differentiating MSCs than T3. This more efficient enhancement of 
hypertrophy could be due to higher BMP4 concentration when BMP4 is added to the 
medium. On the other hand, thyroid hormone could induce regulators that 
ameliorate the effect of up-regulated BMP4-expression. In order to confirm that the 
pro-hypertrophic effect of T3 is mediated by BMP4 we compared BMP4 expression 
between aggregates that were incubated in hypertrophic medium with and without 
T3 and detected significantly higher BMP4 expression in cultures that were 
incubated in medium with T3. This suggests that the thyroid hormone-induced 
enhancement of hypertrophy in this in vitro model is mediated by BMP4. For growth 
plate chondrocytes in mice it was shown that thyroid hormone induces terminal 
differentiation through induction of BMP2 (Ballock, R. T. et al., 2000) and in chick 
growth plate chondrocytes thyroid hormone induces hypertrophy through increased 
BMP4 expression (Lassova, L. et al., 2009). We could not see regulation of BMP2 
expression by thyroid hormone in our model but similar to chick chondrocytes we 
detected regulation of BMP4. This indicates that there are species specific 
differences in the responsiveness to thyroid hormone. In chick chondrocytes and 
human MSCs thyroid hormone induces the expression of BMP4 whereas in mouse 
growth plate chondrocytes BMP2 expression is induced.  
The pro-hypertrophic effect of BMP4 was only seen under hypertrophic conditions in 
which TGFß and dexamethasone were withdrawn. Under chondrogenic conditions 
with continuous application of TGFß and dexamethasone, BMP4 did not elicit the 
enhancement of the hypertrophic phenotype in chondrogenic MSC pellets. It had no 
effect on cell size, ALP activity and collagen type X gene expression. We suppose 
that this is due to TGFß and dexamethasone which are included in the 
chondrogenic medium. TGFß and dexamethasone are known to have anti-
hypertrophic effects in growth plate and chicken sternum chondrocytes (Ballock, R. 
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T. et al., 1993; Leboy, P. S. et al., 1997; Ferguson, C. M. et al., 2000) and we 
suppose that these anti-hypertrophic effects override the pro-hypertrophic effect of 
BMP4 under standard chondrogenic conditions. This phenomenon has been 
observed by other studies. Hanada et al showed that rat MSCs that were treated 
with BMP2 became hypertrophic and that effect was abolished when cells were 
incubated with BMP2 and TGFß (Hanada, K. et al., 2001). Furthermore Sekiya et al 
showed that human MSCs that were treated with BMP4 in the presence of TGFß did 
not develop a hypertrophic phenotype (Sekiya, I. et al., 2005). Other studies 
investigated the effect of different BMPs on MSC hypertrophy with controversially 
results. Schmitt et al showed that BMP2 is not able to induce hypertrophy in human 
MSCs. MSCs that were treated with BMP2 or a combination of BMP2 and TGFß 
differentiated chondrogenically with no signs of hypertrophy (Schmitt, B. et al., 
2003). In contrast rat periosteum-derived progenitor cells treated with BMP2 
developed hypertrophic chondrocytes (Hanada, K. et al., 2001). This indicates that 
there are species specific variations in the responsiveness to different BMPs. In 
human MSCs, Steinert et al showed that both BMP2 and BMP4 gene transfer into 
human MSCs enhance hypertrophy of MSCs (Steinert, A. F. et al., 2009). This result 
is in line with our observation that exogenous applied BMP4 enhances hypertrophy.  
As BMP4 clearly enhanced hypertrophic differentiation of MSCs in the absence of 
anti-hypertrophic TGFß signalling we assumed that inhibition of BMP signalling 
would block hypertrophy in MSCs. In order to investigate this we blocked BMP 
signalling in chondrogenic differentiating MSCs with the BMP inhibitor noggin. 
Noggin binds different BMPs with high affinity to BMP4, 2 and 7 and thereby 
prevents their interaction with the BMP receptor (Zimmerman, L. B. et al., 1996). We 
could show that noggin inhibits the T3 induced hypertrophy in MSCs. Noggin 
treatment reduced the amount and size of hypertrophic cells, ALP activity and 
collagen type X gene expression as well as protein deposition in the extracellular 
matrix under pro-hypertrophic conditions. These result obtained here are consistent 
with studies on embryonic chondrogenesis. In vivo studies showed that over-
expression of the BMP antagonist noggin in the developing chick limb bud prevents 
chondrocyte hypertrophy and the expression of hypertrophic markers like collagen 
type X and ALP (Pathi, S. et al., 1999). Furthermore over-expression of Noggin in 
transgenic mice leads to a lack of hypertrophic chondrocytes (Tsumaki, N. et al., 
2002). In vitro it was shown that noggin prevents T3 stimulation of collagen type X 
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expression in chick chondrocytes (Lassova, L. et al., 2009). Besides the 
suppression of hypertrophy markers, we detected lower expression of collagen type 
II and at 100 ng/ml noggin less metachromatic staining of the extracellular matrix. 
We think that this is due to dedifferentiation of the cells after withdrawal of the 
chondro-inductive growth factor TGFß and blocking of BMP signalling.  
Under standard chondrogenic conditions with continuous application of TGFß and 
dexamethasone, hypertrophy markers are also expressed but to a lower degree 
than in hypertrophic cultures. This phenomenon has been described in various MSC 
cell culture systems and it was shown that after ex vivo transplantation of MSC 
pellets spontaneous hypertrophy, matrix calcification and vascular invasion occurs 
(Pelttari, K. et al., 2006; Bian, L. et al., 2011). To examine whether we can block the 
spontaneous induction of hypertrophy under standard chondrogenic conditions by 
inhibition of BMP signalling, we incubated MSC pellets under chondrogenic 
conditions in the presence of noggin. However, hypertrophy markers such as 
collagen type X expression and ALP activity were not suppressed by noggin. In 
addition there was no effect on collagen type II expression. This suggests that under 
standard chondrogenic conditions other factors than BMP signalling are involved in 
the development and maintenance of this phenomenon.  
Our results showed that BMP signalling associated genes are up-regulated under 
hypertrophic conditions indicating increased BMP signalling activity under 
hypertrophic conditions, especially through strongly increased BMP4 expression. 
Although the effect of BMP signalling on chondrocyte maturation has been 
extensively studied, the mechanisms of BMP effects are not fully understood. It is 
possible that BMP4 also acts via Smad independent pathways. It has been shown 
that BMPs can activate certain MAPK pathways such as TAK1/p38 (Shim, J. H. et 
al., 2009) in a Smad independent manner. In order to further investigate the 
signalling mechanism of BMP4 we analysed the effect of dorsomorphin, a small 
molecule inhibitor that inhibits BMP induced Smad1, 5, 8 phosphorylation by binding 
to the kinase domain of the type I receptor and inhibiting its kinase activity (Yu, P. B. 
et al., 2008; Wrighton, K. H. et al., 2009). Similar to noggin, dorsomorphin inhibits 
T3 induced hypertrophy in a dose dependent manner. The amount of hypertrophic, 
ALP positive cells and collagen type X expression is decreased after dorsomorphin 
treatment. Upon treatment with high dorsomorphin doses, collagen type II staining is 
also decreased and cells dedifferentiate. Under chondrogenic conditions, 
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dorsomorphin had no influence on hypertrophic extend and chondrogenic 
differentiation. No difference in collagen type X and collagen type II staining could 
be detected between chondrogenic control aggregates and dorsomorphin treated 
aggregates. These results are in line with the data observed after noggin treatment. 
Both BMP inhibitors, noggin that blocks the interaction of the ligand with the 
receptor and dorsomorphin that inhibits the activation of Smad1, 5, 8 through the 
activated BMP receptor type I, are able to inhibit T3 induced hypertrophy. This result 
demonstrates that BMP4 signals via Smad-dependent pathway and would suggest 
increased phosphorylation of BMP signalling associated Smad1, 5, 8 under 
hypertrophic conditions. In the Western Blot analysis we did not detect a clear 
difference in the level phosphorylated Smad1, 5, 8 between chondrogenic and 
hypertrophic conditions, whereas in the immunohistochemistry a clear accumulation 
of phospho-Smad1, 5, 8 in the nucleus of hypertrophic cells was detectable. A 
possible explanation for this phenomenon is that for Western Blot analysis whole 
MSC pellets were taken. Histological analysis suggests that in hypertrophic pellets 
less phosopho-Smad1, 5, 8 positive cells are present. We suppose that these are 
the hypertrophic cells that are surrounded by dedifferentiated cells or apoptotic cells 
that do not express phospho-Smad1, 5, 8. The staining of these hypertrophic 
Smad1, 5, 8 positive cells is very strong and seems to accumulate in the nucleus, 
where phopho-Smad1, 5, 8 acts as transcription factor to regulate gene expression. 
In contrast, in chondrogenic pellets more cells express phosopho-Smad1, 5, 8 but to 
a lower degree. We think that these are the chondrogenic cells that show low BMP 
signalling activity due to intrinsic BMP signalling. Recent studies furthermore 
showed that TGFß can also induce Smad1, 5 phosphorylation in different cell types 
including mesenchymal cells independent of BMP signalling (Goumans, M. J. et al., 
2002; Goumans, M. J. et al., 2003; Daly, A. C. et al., 2008; Liu, I. M. et al., 2009; 
Wrighton, K. H. et al., 2009). This may also explain the high phospho-Smad1, 5, 8 
signal under chondrogenic conditions in the Western Blot analysis.  
Real time PCR revealed increased BMP2 expression at the beginning of 
chondrogenic differentiation on culture day 3 and Western Blot analysis for Smad1, 
5, 8 revealed activated BMP signalling throughout the chondrogenic pre-
differentiation phase. Based on these findings we were interested whether BMP 
signalling during early phases of chondrogenic differentiation is important for priming 
cells for later hypertrophic differentiation. Maybe the time point of BMP inhibition 
Discussion 
94 
plays a role in the induction of hypertrophy in MSCs. In the previous experiments 
noggin and dorsomorphin treatment started on day 14, after the chondrogenic pre-
differentiation phase. In the following MSC pellets were treated with dorsomorphin 
during the chondrogenic pre-differentiation phase and then transferred to 
hypertrophic or chondrogenic medium, or were treated with dorsomorphin over the 
whole culture period. 
Inhibition of BMP signalling during the chondrogenic pre-differentiation phase from 
day 1 until day 14, followed by incubation in hypertrophic medium severely disturbs 
hypertrophic differentiation. Low doses of dorsomorphin reduce the amount of 
hypertrophic, ALP positive cells and collagen type X staining. This indicates that 
inhibition of BMP signalling during early phases of chondrogenic differentiation 
reduces hypertrophy. Higher doses of dorsomorphin lead to the dedifferentiation of 
the cells with no collagen type II expression. We suppose that inhibition of BMP 
signalling during the chondrogenic pre-differentiation phase disturbs chondrogenic 
differentiation and makes the cells more susceptible for the deprivation of TGFß on 
day 14. In general, we hypothesize that if the cells reach a certain level of 
chondrogenic differentiation during the chondrogenic pre-differentiation phase, they 
become hypertrophic after deprivation of TGFß. But if the cells do not reach this 
differentiation level, they dedifferentiate after deprivation of TGFß.  
Under chondrogenic conditions, inhibition of BMP signalling during early stages of 
chondrogenic differentiation does not inhibit the expression of hypertrophy markers 
as there is no difference in collagen type X deposition between control and 
dorsomorphin treated aggregates. Interestingly, inhibition of BMP signalling with 
high doses of dorsomorphin over the whole culture period reduces the expression of 
hypertrophic markers like collagen type X and ALP. However, both inhibition of BMP 
signalling during the pre-differentiation phase and over the whole culture period 
does no influence chondrogenic differentiation and does not lead to a 
dedifferentiation of the cells. The fact that under chondrogenic conditions, inhibition 
of BMP signalling over the whole culture period inhibits the expression of the 
hypertrophy markers collagen type X and ALP but does not reduce the 
chondrogenic marker collagen type II is a promising approach for the use of MSCs 
in articular cartilage repair. However our results are only based on 
immunohistochemical analysis and additional, more sensitive assays, for example 
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real time PCR analysis of chondrogenic and hypertrophic markers after 
dorsomorphin treatment are needed to confirm this observation.  
The common observation that under hypertrophic conditions after inhibition of BMP 
signalling with high doses of noggin or dorsomorphin cells dedifferentiated is 
presumably due to the combination of withdrawal of TGFß and inhibition of BMP 
signalling. Under chondrogenic conditions the continuous application of TGFß 
promotes chondrogenic differentiation and prevents the cells from dedifferentiating 
after inhibition of BMP signalling. TGFß signalling seems to be sufficient for 
chondrogenic differentiation of MSCs and BMP signalling is not needed as further 
pro-chondrogenic stimulus. Studies on MSC chondrogenesis pointed towards a pro-
chondrogenic role of BMPs. A recent work from Sekiya demonstrated that BMP2, 
BMP4 and BMP6 combined with TGFß3 induced chondrogenic phenotype in 
cultured bone marrow derived human MSC pellets (Sekiya, I. et al., 2005). In 
contrast, in this model of chondrogenic differentiating MSCs BMP signalling is not 
required for chondrogenic differentiation as long as TGFß is in the medium. 
Furthermore our results showed that the addition of BMP4 to chondrogenic medium 
does not increase chondrogenic markers like collagen type II. This observation is 
accordant with results from Barry et al demonstrating that TGFß3 alone is sufficient 
for chondrogenic differentiation in human MSCs derived from bone marrow (Barry, 
F. et al., 2001) whereas synovium derived MSCs needed BMP2 and TGFß for 
optimal chondrogenic differentiation (Shirasawa, S. et al., 2006). 
In summary, we could show that hypertrophy in MSCs is enhanced by thyroid 
hormone via induction of BMP4 and BMP4 is a potent regulator in late differentiation 
stages in chondrifying MSCs. This thyroid hormone-induced enhancement of 
hypertrophy by BMP4 can be inhibited with the BMP antagonists noggin and 
dorsomorphin. Both BMP inhibitors had no effect under standard chondrogenic 
conditions when applied after the chondrogenic pre-differentiation phase, however 
inhibition of BMP signalling with dorsomorphin over the whole culture period 
reduced hypertrophic marker like collagen type X but not chondrogenic marker like 
collagen type II. The goal in cartilage tissue engineering is to generate 
phenotypically stable articular cartilage. Therefore it is important to develop effective 
methods to maintain the articular phenotype without hypertrophy. Attempts to avoid 
hypertrophic differentiation during MSC chondrogenesis based on the use of 
molecules that display an inhibitory effect during growth plate development have 
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been developed. Delayed addition of PTHrP or FGF during in vitro chondrogenesis 
of MSCs have been shown to inhibit the expression of collagen type X but also that 
of collagen type II (Mwale, F. et al., 2010; Weiss, S. et al., 2010; Mueller, M. B. et 
al., 2013). Here we demonstrated that under chondrogenic conditions, prolonged 
incubation of MSC pellets with the BMP inhibitor dorsomorphin inhibits the 
expression of collagen type X but does not reduce collagen type II expression. The 
use of dorsomorphin or other BMP inhibitors may be a promising approach to inhibit 
hypertrophy in chondrogenic differentiating MSCs, however further analysis of gene 
expression of hypertrophic and chondrogenic markers after prolonged dorsomorphin 
treatment are needed to confirm preliminary histological analysis.  
The BMP signalling pathway is regulated by different BMP antagonists. Soluble 
BMP antagonists bind BMPs and prevent their interaction with the receptor. During 
development, the functions of BMPs are spatially and temporally regulated by 
different specific antagonists. We hypothesized that BMP antagonists could play a 
role in the regulation of MSC hypertrophy by antagonizing BMP signalling. During 
skeletal development noggin is expressed in condensing cartilage and in immature 
chondrocytes (Brunet, L. J. et al., 1998). This indicates that noggin antagonizes 
BMP signalling in immature chondrocytes and prevents them from hypertrophic 
differentiation. In addition, two human genetic disorders, symphalangism and 
multiple synostoses syndrome are caused by a mutation in the noggin gene and are 
characterized by bony fusions of the joints (Gong, Y. et al., 1999). In the in vitro 
hypertrophy model, we found that noggin is significantly down-regulated during early 
phases of MSC hypertrophy indicating a role of noggin in the induction of MSC 
hypertrophy. Chordin, another BMP antagonist, is highly expressed in the 
proliferation zone and very low in the hypertrophic zone of the growth plate during 
limb development. This indicates a role of chordin in the regulation of BMP 
signalling activity during chondrocyte maturation (Zhang, D. et al., 2002). 
Furthermore, ectopic expression of chordin in the developing limb results in a 
delayed chondrocyte hypertrophy (Zhang, D. et al., 2002). In the in vitro hypertrophy 
model we detected a significant down-regulation of chordin on day 28 in 
hypertrophic pellets. It is possible that noggin and chordin cooperate to regulated 
BMP signalling activity during hypertrophic differentiation. During early phases of 
hypertrophic differentiation, noggin is down-regulated and during later phases of 
hypertrophic differentiation chordin is down-regulated leading to increased BMP 
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signalling. Surprisingly, the BMP antagonist gremlin is expressed in an opposing 
manner. Gremlin is up-regulated under hypertrophic conditions in the in vitro 
hypertrophy model. The function of this up-regulation is unclear. Gremlin has been 
shown to be highly expressed in non-dividing and terminally differentiated cells and 
induces apoptosis (Merino, R. et al., 1999). It is possible that gremlin induces 
apoptosis of hypertrophic cells. Gremlin has also been shown to be pro-
angiogenetic (Stabile, H. et al., 2007). During endochondral ossification hypertrophic 
chondrocytes release angiogenetic factors like VEGF to attract blood vessels. 
Maybe gremlin has a similar function. Early phases of OA are characterized by 
hypertrophy of articular chondrocytes. Interestingly, during that phase BMP4 and 
gremlin are up-regulated (Nakase, T. et al., 2003; Tardif, G. et al., 2004; Tardif, G. 
et al., 2009). BMP4 induces gremlin expression in OA chondrocytes (Tardif, G. et 
al., 2004). In normal articular cartilage BMP4 is only expressed to a low degree. 
This indicates a critical role of BMP4 and gremlin in the induction of differentiation of 
normally stable articular chondrocytes towards hypertrophic chondrocytes. Similar to 
this we detected an increased expression of BMP4 and gremlin under hypertrophic 
conditions. More examinations are needed to unravel the role of gremlin in MSC 
hypertrophy.  
BAMBI is a transmembrane protein with structural similarity to TGFß and BMP 
receptor type I, but lacks the intracellular kinase domain. BAMBI is able to inhibit 
both TGFß and BMP signalling. BAMBI has been shown to be co-expressed with 
BMP4 during xenopus and mouse embryogenesis (Onichtchouk, D. et al., 1999; 
Grotewold, L. et al., 2001) and BMP4 induces BAMBI expression. We detected a 
significant up-regulation of BAMBI under hypertrophic conditions. The function of 
this strong up-regulation is unclear. Preferential inhibition of TGFß signalling could 
diminish the anti-hypertrophic effect of TGFß which would result in further 
enhancement of the hypertrophic phenotype. On the other hand, predominant 
interaction with BMP receptors could ameliorate the BMP induced terminal 
differentiation in our pro-hypertrophic culture conditions. BAMBI may act as a 
negative feedback loop to inhibit BMP signalling in response to increased BMP4 
expression. The clear up-regulation of BAMBI in our experiment suggests that 
BAMBI is a modulator in terminal differentiation in MSC chondrogenesis. To clarify 
the role of BAMBI in MSC chondrogenesis, functional experiments with knock-down 
and overexpression of BAMBI started. 
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5.3 Influence of TGFß signalling on MSC hypertrophy 
Endochondral ossification is a highly regulated process that involves the interaction 
of different signalling pathways. Besides BMP signalling, TGFß signalling plays a 
crucial role during chondrocyte proliferation, differentiation and maturation and 
TGFß is abundantly expressed in the growth plate (Matsunaga, S. et al., 1999). 
TGFß signalling has been shown to stimulate chondrogenesis of mesenchymal cells 
and embryonic chondrocytes in vitro and in vivo (Seyedin, S. M. et al., 1986; Joyce, 
M. E. et al.; Schofield, J. N. & Wolpert, L., 1990; Leonard, C. M. et al., 1991; Chimal-
Monroy, J. & Diaz de Leon, L., 1997; Lorda-Diez, C. I. et al.). Similar to this, in the 
cell culture system we use here MSC chondrogenesis is induced by TGFß1. Prior 
work also demonstrated that lowering the TGFß1 concentration decreases 
chondrogenesis in MSC pellets (Johnstone, B. et al., 1998). Besides the importance 
of TGFß during chondrocyte differentiation, TGFß has been shown to prevent 
chondrocyte maturation during skeletal development by keeping cells in a pre-
hypertrophic state. In vitro studies with different chondrocyte cell culture models 
demonstrated that TGFß treatment inhibits maturation of chondrocytes into 
hypertrophic cells (Gelb, D. E. et al., 1990; Ballock, R. T. et al., 1993; Ferguson, C. 
M. et al.). In addition Ferguson et al. showed that during in vivo skeletogenesis 
increased TGFß signalling inhibits chondrocyte maturation and expression of 
hypertrophy associated genes like collagen type X (Ferguson, C. M. et al., 2004). 
We believe that TGFß also inhibits MSC hypertrophy in our cell culture system. 
Chondrogenic differentiating MSCs are induced to increase their hypertrophic 
phenotype by deprivation of TGFß and the addition of T3. The withdrawal of TGFß 
is a prerequisite for the enhancement of hypertrophy. The continuous application of 
TGFß under chondrogenic standard conditions seems to slow down MSC 
maturation. This was confirmed by our study. We were able to demonstrate that 
deprivation of TGFß and dexamethasone from the medium increases hypertrophy 
compared to medium with TGFß and dexamethasone. This is a first hint that TGFß 
seems to inhibit MSC hypertrophy. In order to further investigate the role of TGFß 
signalling on MSC hypertrophy we compared the expression of TGFß associated 
genes between chondrogenic and hypertrophic conditions in the in vitro hypertrophy 
model. Besides the reduced exogenous application of TGFß under hypertrophic 
conditions we wanted to investigate whether intrinsic TGFß signalling is down-
regulated under hypertrophic conditions. Real time PCR revealed that TGFß 
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receptors are down-regulated under hypertrophic conditions. The TGFßR1 is 
significantly down-regulated on day 17, day 21 and day 28 in hypertrophic MSC 
pellets. This result was confirmed on protein level using Western Blot analysis 
where we detected reduced TGFßR1 protein in hypertrophic MSC pellets. In 
addition, the TGFßR2 is down-regulated on day 28 in hypertrophic pellets. These 
findings are in accordance with the notion that transgenic mice that express a 
defective TGFßR2, have been shown to have increased hypertrophic differentiation 
and premature collagen type X expression in the growth plate and develop early 
osteoarthritis characterized by the replacement of articular cartilage by hypertrophic 
cartilage and bone (Serra, R. et al., 1997). Based on these results we hypothesized 
that under hypertrophic conditions TGFß signalling is reduced through 1) deprivation 
of TGFß in the medium and 2) reduced TGFß receptor expression. Indeed Western 
Blot analysis for TGFß signalling associated Smad2 and 3 revealed decreased 
amounts of phospho-Smad2 and phospho-Smad3 under hypertrophic conditions. 
We suppose that this reduced TGFß signalling under hypertrophic conditions 
contributes to the enhancement of the hypertrophic phenotype. TGFß signalling has 
been shown to induce the expression of the transcription factor Sox9 (Chimal-
Monroy, J. et al., 2003; Furumatsu, T. et al., 2009). During skeletal development in 
the growth plate, Sox9 is expressed in all chondrocyte progenitors and 
chondrocytes but its expression is completely turned off in hypertrophic 
chondrocytes (Ng, L. J. et al., 1997; Zhao, Q. et al., 1997). Sox9 is a key 
transcription factor in chondrocyte differentiation (Lefebvre, V. et al., 1998) and 
negatively regulates maturation of chondrocytes to the hypertrophic stage. Down-
regulation of Sox9 is required for chondrocyte hypertrophy. Based on this we 
supposed that decreased TGFß signalling under hypertrophic conditions leads to 
decreased Sox9 expression that then leads to hypertrophic differentiation. Gene 
expression of Sox9 in the in vitro hypertrophy model showed that Sox9 is down-
regulated in hypertrophic MSC pellets on day 17 and day 21, however on day 28 
there is a tendency towards reduced Sox9 expression under hypertrophic 
conditions, but not significantly. Protein analysis for Sox9 using Western Blot 
provided similar results. Sox9 protein is decreased on day 21 under hypertrophic 
conditions but not on day 28. The reason for this phenomenon is unclear. Loss of 
function models of TGFß showed that decreased TGFß signalling increases 
chondrocyte hypertrophy in vivo (Serra, R. et al., 1997; Yang, X. et al., 2001). To 
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determine whether the reduction of TGFß signalling in our cell culture system 
increases hypertrophy in chondrogenic differentiating MSCs we used the TGFß 
inhibitor SB431542, a potent inhibitor of TGFßR1 kinase activity (Callahan, J. F. et 
al., 2002). Under chondrogenic conditions, where normally TGFß signalling activity 
is very high, inhibition of TGFß signalling does not increase hypertrophy. However, 
high doses of the TGFß inhibitor lead to a dedifferentiation of the pellets. This was 
shown by decreased metachromic DMMB staining and decreased collagen type II 
staining. This demonstrates that the pure reduction of TGFß signalling leads to a 
dedifferentiation of the cells rather than to an increased hypertrophy.  
Our results demonstrated that BMP4 has strong pro-hypertrophic properties and is 
able to increases hypertrophy under hypertrophic conditions but failed to increase 
hypertrophy under chondrogenic conditions in the presence of TGFß. We could 
show that a combined treatment of MSC pellets under chondrogenic conditions with 
the TGFß inhibitor and the pro-hypertrophic BMP4 is able to increase hypertrophy. 
This was demonstrated by an increased amount of hypertrophic and ALP positive 
cells and increased collagen type X staining. Furthermore dedifferentiation of the 
pellets with high doses of the TGFß inhibitor is prevented with BMP4 treatment. In 
conclusion a simultaneous reduction in TGFß signalling activity together with 
activation of BMP signalling is needed to push the cells towards a hypertrophic cell 
fate. The pure reduction of TGFß signalling is not sufficient to increase hypertrophy. 
Similar to this we already showed that under standard chondrogenic conditions with 
high TGFß signalling activity, the addition of BMP4 is not sufficient to induce 
hypertrophy. Both TGFß and BMP signalling have to be modulated, TGFß signalling 
has to be decreased and BMP signalling has to be increased, to change the 
phenotype of the cells.  
In addition to the clearly demonstrated involvement of TGFß and BMP signalling in 
this model, our data suggest that dexamethasone may contribute to the regulation of 
hypertrophy in our model. Our results showed that withdrawal of TGFß and 
dexamethasone (hyp-T3) increases the hypertrophic phenotype compared to 
standard chondrogenic conditions but to a much lower extent than after additional 
application of T3 (Figure 17, 18). In the experiments with the TGFß inhibitor 
SB431542 (Figure 40), inhibition of TGFß mediated Smad2 and Smad3 activation 
without withdrawal of dexamethasone does not induce this mild hypertrophic 
phenotype. Steroids like dexamethasone have been shown to inhibit hypertrophy in 
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growth plate chondrocytes (Leboy, P. S. et al., 1997). One possible explanation for 
this difference in the response of cells to application of the TGFß inhibitor compared 
to the withdrawal of TGFß and dexamethasone is that dexamethasone can have an 
inhibitory effect on hypertrophy in chondrogenic MSC cultures. On the other hand, 
the activation of other signalling pathways than Smad2 and Smad3 activation by 
TGFß may contribute to that. Similar to the experiments with the TGFß inhibitor, the 
combination of TGFß and dexamethasone withdrawal and the addition of BMP4 
leads to a more pronounced hypertrophic phenotype than the addition of BMP4 with 
blocking of TGFß mediated Smad2 and Smad3 activation in the presence of 
dexamethasone (Figure 18, 41). This difference may be explained again by an 
inhibitory effect of dexamethasone on hypertrophy. The effect of dexamethasone on 
MSC hypertrophy could be investigated by additional functional experiments. 
Under hypertrophic conditions TGFß signalling is already relatively low due to 
deprivation of TGFß from the medium and eventually intrinsic TGFß signalling is 
decreased through a reduction in TGFß receptor expression. Inhibition of the 
residual TGFß signalling activity did not further increase hypertrophy. The pellets 
that were treated with the TGFß inhibitor differentiated to a hypertrophic phenotype 
similar to that of standard hypertrophic conditions. This result is not surprising as we 
demonstrated that TGFß signalling activity is already very weak under hypertrophic 
conditions and inhibition of this minor intrinsic TGFß signalling activity has no further 
effect on the hypertrophic outcome. Of note, high doses of the TGFß inhibitor do not 
lead to a dedifferentiation of the cells, presumably the activated BMP signalling 
under hypertrophic conditions preserves the cells form dedifferentiating.  
Here we could show that under hypertrophic conditions TGFß signalling is 
decreased through down-regulation of TGFß receptors and the deprivation of TGFß 
from the medium. This contributes to the increased hypertrophic phenotype under 
hypertrophic conditions. Additional inhibition of intrinsic TGFß signalling does not 
further increase hypertrophy based on histology. Inhibition of TGFß signalling under 
chondrogenic conditions does not increase hypertrophy however inhibition of TGFß 
signalling together with addition of BMP4 increases hypertrophy. Similar to this, In 
vivo studies showed that inhibition of TGFß signalling with loss of function models of 
TGFß increased chondrocyte hypertrophy (Serra, R. et al., 1997; Yang, X. et al., 
2001). In these in vivo studies growth factors like BMPs are expressed and available 
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in the growth plate and might, together with the reduced TGFß signalling, promote 
chondrocyte hypertrophy. 
 
In summary the results obtained in this study bring some light into the regulation of 
hypertrophy in MSC chondrogenesis. Our results provide evidence that MSC 
hypertrophy is dependent on a balance between TGFß and BMP signalling. The 
current experimental data support the following working model: in the absence of 
both, TGFß and BMP signalling MSCs dedifferentiate characterized by decreased 
collagen type II expression. Reduced TGFß signalling and active BMP signalling 
leads to hypertrophic differentiation of the cells. Active TGFß signalling and active 
BMP signalling as well as active TGFß signalling and reduced BMP signalling lead 
to chondrogenic differentiation of the cells. 
 
 
 
Figure 44. Model for the influence of BMP and TGFß signalling in the regulation of MSC 
hypertrophy. 
 
 
These data provide valuable information for the use of MSCs in articular cartilage 
repair. Both conditions are artificial in vitro conditions and the ultimate goal in 
cartilage tissue engineering will be the generation of in vivo phenotypically stable 
articular cartilage. As tissue engineering constructs will be exposed to factors like 
thyroid hormone, BMPs and TGFß these results have in vivo relevance and add 
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important information to the knowledge of the biology of especially the late 
differentiation stages in MSC chondrogenesis. These results may help to find ways 
to improve the performance of MSC-based cartilage constructs in vivo. Finally, 
advantage of this for cartilage tissue engineering unfavourable enhancement of 
hypertrophy by thyroid hormone or BMP4 can be taken for the repair of critical size 
bone defects. Endochondral ossification via hypertrophic cartilage takes place in 
both bone development and secondary fracture healing (Kronenberg, H. M., 2003) 
and hypertrophic engineered cartilage has been suggested as a template for bone 
defect repair (Scotti, C. et al., 2010; Farrell, E. et al., 2011).  
5.4 Involvement of other signalling pathways in MSC hypertrophy 
Multiple signalling pathways are involved in the regulation of growth plate 
chondrogenesis and hypertrophy. Besides BMP and TGFß signalling, other 
signalling pathways have been implicated in the regulation of embryonic 
chondrogenesis including FGF signalling, Hedgehog signalling and Wnt signalling. 
We investigated the gene expression of signalling molecules involved in these 
pathways comparative between chondrogenic and hypertrophic conditions using 
microarray analysis. Preliminary results from one patient showed that genes 
involved in these pathways are differentially expressed in the in vitro hypertrophy 
model. FGF ligands and FGF receptors are differentially expressed between 
chondrogenic and hypertrophic conditions. Indian hedgehog (IHH) and the IHH 
receptor Patched 1 (PTCH1) are up-regulated under hypertrophic conditions. Wnt 
receptor and co-receptor expression is increased and the expression of the Wnt 
inhibitor DKK1 is decreased under hypertrophic conditions. These preliminary data 
provide evidence that these signalling pathways may be involved in the regulation of 
MSC chondrogenesis and hypertrophy. However the results from this analysis were 
derived from cells of only one donor and need to be confirmed by further 
experiments.   
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